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Abstract 
Prostate cancer is currently one of the most prevalent types of cancer in men. The 
development of prostate tumors has long been known to require exposure to androgens, 
and several important pathways governing cell growth have been found to be deregulated 
in prostate tumorigenesis. Recent genetic studies have revealed that complex gene fusions 
and copy - number alterations are frequent in prostate cancer, which is a unique feature 
among solid tumors. These chromosomal aberrations are though to arise as a consequence 
of faulty repair of DNA double strand breaks (DSB). Most repair mechanisms have been 
studied in detail in cancer cell lines, but how DNA damage is detected and repaired in 
normal differentiated human cells has not been widely addressed. The events leading to 
the gene fusions in prostate cancer are under rigorous studies, as they not only shed light 
on the basic pathobiologic mechanisms but may also produce molecular targets for 
prostate cancer treatment and prevention. 
Prostate and seminal vesicles are part of the male reproductive system. They share 
similar structure and function but differ dramatically in their cancer incidence. 
Approximately fifty primary seminal vesicle carcinomas have been reported worldwide. 
Surprisingly, only little is known on the reasons why seminal vesicles are resistant to 
neoplastic changes. As both tissues are androgen dependent, it is truly a mystery that 
androgen signaling would only lead to tumors in prostate tissue. 
In this work, we set up novel ex vivo – human tissue culture models of prostate and 
seminal vesicles, and used these to study how DNA damage is recognized and repaired in 
normal epithelium. Activation of a major DNA - damage inducible pathway, mediated by 
the ATM kinase, was robustly activated in all main cell types of both tissues. Interestingly, 
we discovered that secretory epithelial cells had less histone variant H2A.X (H2AX) and 
after DNA damage much lower levels of H2AX was phosphorylated on serine 139 
(γH2AX) than in basal or stromal cells. γH2AX has been considered essential for efficient 
DSB repair, but as there were no significant differences in the γH2AX levels between the 
two tissues, it seems more likely that the role of γH2AX is dispensable in postmitotic cells. 
We also gained insight into the regulation of p53, an important transcription factor that 
protects genomic integrity via multiple mechanisms, in human tissues. DSBs did not lead 
to a pronounced activation of p53, but treatments causing transcriptional stress, on the 
other hand, were able to launch a notable p53 response in both tissue types. In general, ex 
vivo – culturing of human tissues provided unique means to study differentiated cells in 
their relevant tissue context, and is suited for testing novel therapeutic drugs before 
clinical trials. 
In order to study how prostate and seminal vesicle epithelial cells are able to activate 
DNA damage – induced cell cycle checkpoints, we used cultures of primary prostate and 
seminal vesicle epithelial cells. To our knowledge, we are the first to report isolation of 
 
 
 
 
human primary seminal vesicle cells. Surprisingly, human prostate epithelial cells did not 
activate cell cycle checkpoints after DSBs in part due to low levels of Wee1A, a kinase 
regulating CDK activity, while primary seminal vesicle epithelial cells possesses 
proficient cell cycle checkpoints and expressed high levels of Wee1A. Similarly, seminal 
vesicle cells showed a distinct activation of the p53 - pathway after DSBs that did not 
occur in prostate epithelial cells. This indicates that p53 protein function is under different 
control mechanisms in the two cell types, which together with proficient cell cycle 
checkpoints may be crucial in protecting seminal vesicles from endogenous and 
exogenous DNA damaging factors and, as a consequence, from carcinogenesis. 
These data indicate that two very similar organs of male reproductive system do not 
respond to DNA damage in a similar manner. The differentiated, non - replicating cells of 
both tissues were able to recognize DSBs, but under proliferation human prostate 
epithelial cells had deficient activation of the DNA damage response. This suggests that 
prostate epithelium is most vulnerable to accumulating genomic aberrations under 
conditions where it needs to proliferate, for example after inflammatory cellular damage. 
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Abbreviations 
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JNK c - Jun N - terminal kinase 
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MDC1 mediator of DNA - damage checkpoint 1 
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Introduction 
Prostate cancer causes significant morbidity and mortality in the western countries. It 
affects more than 4000 men in Finland every year, and poses diagnostic and therapeutic 
challenges. Although the molecular events leading to prostate neoplasms are beginning to 
emerge, we still do not know why prostate cancer is so common. Recent research has 
indicated that prostate adenocarcinomas harbor a high number of chromosomal aberrations 
that are uncommon in other solid tumors. First fusion between androgen regulated 
transmembrane serine protease isoform 2 (TMPRSS2) gene and a transcription factor E - 
twenty six transcription factor family (ETS) - family member v - ets erythroblastosis virus 
E26 oncogene homolog (ERG) was described 2005, and since then other gene fusions have 
been reported. The fusion genes deregulate many important pathways controlling cell 
growth and proliferation, one the most well - known among them being androgen signaling 
pathway. The exact mechanisms that lead to accumulation of gene fusions in prostate 
cancer are currently unknown, but they are though to arise from misrepaired DNA double 
strand breaks (DSBs). One of the repair pathways important in DSB repair, non -
homologous end joining (NHEJ), has been implicated. Therefore, thorough understanding 
of DNA damage recognition and repair in normal prostate epithelium helps shed light on 
early events in prostate tumorigenesis. 
Seminal vesicles are a part of the male reproductive system and are located at the base of 
the prostate. Prostate and seminal vesicles are both androgen dependent and share a similar 
structure and function. Remarkably, primary seminal vesicle carcinomas are extremely rare, 
as only some 50 cases have been reported worldwide. Therefore, there must be fundamental 
differences in either the nature and amount of DNA damage, or the way the two tissues are 
able to recognize and repair DNA damage. Together prostate and seminal vesicles form an 
ideal model to study the consequences of DNA damage in slowly renewing human 
epithelium. 
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Review of the literature 
1. DNA damage, genomic instability and prostate cancer 
1.1. DNA damage as a cause of cancer 
Cancer arises as a result of accumulating mutations in the genetic material of eukaryotic 
cells (Stratton et al., 2009). The structure of double - stranded DNA (dsDNA) is inherently 
rather stable, and multiple pathways have evolved to monitor and maintain the integrity of 
the genome (Hoeijmakers, 2001). Nonetheless, endogenous and exogenous stress factors 
constantly challenge the stability of the DNA and occasionally genetic lesions escape the 
correct repair mechanisms. Over time more and more genetic aberrations are fixed into the 
genomes of our cells and gateway to cancer is opened (Stratton et al., 2009).  
There are several distinct classes of somatic mutations that are created by different 
mechanisms: changes of a single base to another, insertions or deletions of DNA segments, 
changes in gene copy number or chromosomal rearrangements where two pieces of DNA 
are falsely joined together. Epigenetic changes do not change the DNA sequence itself but 
alter the transcription of genes and can thus affect the phenotype of a cancer cell. 
Completely new DNA sequences may be introduced into DNA by tumor viruses. The rate 
and type of somatic mutations depends on many factors, including the nature of genotoxic 
stress and cell type. For example, proliferating epithelial cells of the colon are much more 
likely to accumulate mutations due to DNA polymerase errors than quiescent neurons. Not 
all somatic mutations contribute to tumorigenesis, as most of them do not give cells any 
clonal growth advantage. This type of changes are called passenger mutations, as they are 
propagated in cancer cells passively by the rare number of mutations that are required to 
deregulate normal growth programs. It has been estimated that around five - seven genetic 
alterations are needed to convert normal cells into cancer cells (Schinzel and Hahn, 2008). 
As these changes drive the tumor formation, they are called the driver mutations. 
In the updated version of the most cited review article on cancer Hanahan and Weinberg 
list genomic instability and mutation as an enabling characteristic that allows the 
acquisition of cancer cell hallmark properties (Hanahan and Weinberg, 2011). Others have 
proposed that genomic instability is such an essential feature of cancer cells, that is 
warrants it to be called as a hallmark of cancer (Negrini et al., 2010). There are different 
forms of genomic instability. Chromosomal instability (CIN) can be further divided into 
changes of chromosome structure or number. Microsatellite instability (MSI) changes the 
number of oligonucleotide repeats in microsatellite regions, and increases the frequency of 
base - pair mutations. Genomic instability in hereditary cancers is often due to inactivation 
 
 
 
 
14 
of the caretaker genes, e.g. ataxia – telangiectasia mutated (ATM) in ataxia telangiectasia (A 
- T) or BRCA1 or BRCA2 in hereditary breast cancer, but the source of genomic instability 
in non - hereditary cancer cases is still unclear (Negrini et al., 2010). High - throughput 
sequencing studies suggest that mutations in DNA repair genes are infrequent and that it is 
rather oncogene-induced replicative stress that acts a source of genomic instability in 
sporadic human tumors (Negrini et al., 2010). 
1.1.1. Mechanisms protecting cells from tumorigenesis 
Hanahan and Weinberg (2011) list three pathways that are important in maintaining 
genomic integrity: p53, “the guardian on the genome”, that is central in monitoring DNA 
damage and orchestrating a proper cellular response after such events; caretakers of the 
genome that directly detect and repair damaged DNA or inactivate DNA damaging agents; 
and telomerase enzyme that protects telomeric DNA and thus guards karyotypic stability. 
These molecules are indeed essential for preventing multistep tumor progression. 
Maintenance of genomic integrity in multicellular organisms requires the concerted action 
of many partially overlapping pathways that control DNA repair, cell cycle progression, 
fidelity of DNA replication and segregation, protection of chromosomal ends, senescence 
and apoptosis (Harper and Elledge, 2007; Rouse and Jackson, 2002 and Figure 1.). 
Collectively, all the responses designed to minimize the impact of DNA damage via 
promotion of DNA repair and cell cycle checkpoints are referred to as DNA damage 
response (DDR) (Ciccia and Elledge, 2010; Jackson and Bartek, 2009). 
 
Figure 1. DNA damage activates various signaling pathways aimed at maintenance of genomic 
integrity. 
Eukaryotic cells have several different DNA damage repair pathways. Each pathway is 
responsible for the repair of only certain types of DNA damage (Hakem, 2008). Sometimes 
it is possible to directly reverse the DNA damage. For example, the enzyme mammalian O6 
– methylguanine - DNA methyltransferase (MGMT) is able to remove alkyl groups from 
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damaged bases without further ado. For more complex lesions, more complex repair 
pathways are required. Mismatch repair pathway (MMR) detects and repairs small 
insertions and deletions that occur during DNA replication. It seems to be important 
especially in the gastrointestinal tract. Failure of this pathway commonly results in MSI. 
Nucleotide excision repair (NER) is required for removal of lesions that distort the DNA 
double helix, such as bulky DNA adducts (Cleaver, 2005), whereas base excision repair 
(BER) is able to replace damaged bases with new nucleotides. For the repair of DSBs, the 
most lethal form of DNA damage, there are two main pathways called homologous 
recombination (HR) and NHEJ (Sarasin and Stary, 2007; Sonoda et al., 2006). HR is said 
to be error - free, as it is able to use the sister chromatid as a template for the repair. On the 
other hand, this limits HR only to certain phases of cell cycle, when homologous 
chromosomes are available (Branzei and Foiani, 2008). NHEJ is the predominant pathway 
for DSB repair in mammalian cells. It is able to ligate broken DNA ends together in all the 
cell cycle phases, especially in G1, but is unable to prevent DNA base loss in the process 
and is thus called error - prone. The core components of NHEJ are Ku70 and Ku80 proteins 
that recognize broken DNA ends, DNA-dependent protein kinase, catalytic subunit (DNA - 
PKcs) that complexes with Ku proteins to form the functionally active DNA - PK complex 
that phosphorylates other DNA repair targets and is together with Artemis involved in end 
processing, and XRCC4 and DNA ligase IV (LigIV) that perform the final ligation of the 
damaged DNA ends (Mahaney et al., 2009). 
Cell cycle regulation constantly monitors mitogenic and anti - mitogenic signaling and 
thus prevents unscheduled proliferation. There are four phases in the cell cycle: G1, S, G2 
and M. Cells replicate their DNA during S - phase, in M - phase they divide into two 
daughter cells, and the gap phases in between are called G1 and G2. Cyclins and cyclin – 
dependent kinases (CDKs) form the engine that drives the cell cycle, and CDK activity is 
further modulated by CDK - inhibitors of Ink4, Cip and Kip – families. Proper progression 
through these phases is monitored by several cell cycle checkpoints that verify successful 
completion of each phase of cell cycle before progression into the next one and sense 
possible defects in DNA synthesis and chromosome segregation. This machinery is 
commonly deregulated in human cancer (Malumbres and Barbacid, 2009). DNA damage is 
often said to activate cell cycle checkpoints, although a more proper term, when talking 
about the signaling cascades that arrest cell cycle progression until DNA damage is 
repaired, would be ‘DNA damage checkpoints’. Nonetheless, activation of both of these 
checkpoints leads to inhibition of CDK - activity (Cerqueira et al., 2009), which justifies 
the overlapping use of the term cell cycle checkpoints. The checkpoints have an important 
role in tumorigenesis, as their defects can lead to unscheduled proliferation, increased 
number of mutations and changes in chromosome structure and number (Kastan and 
Bartek, 2004; Malumbres and Barbacid, 2009). 
In the face of extensive DNA damage, which cannot be repaired, the cells can be 
permanently removed via apoptosis, or may be directed into senescence. The choice 
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between senescence and apoptosis is influenced by the cell type and nature of the damage. 
Cellular senescence is a state of permanent inability to proliferate. It is caused by severe 
stress, and thus differs from quiescence and terminal differentiation (d'Adda di Fagagna, 
2008). It is thought to form a barrier against tumorigenesis, as senescent cells have been 
detected in premalignant lesions and maintenance of the senescent phenotype has been 
linked to tumor suppressors INK4A, ARF and p53 (Collado and Serrano, 2010). There are 
several forms of senescence distinguished by the inducing event: telomere shortening of 
normal cells leads to replicative senescence, overexpression of oncogenes results in 
oncogene-induced senescence (OIS), and senescence triggered by excessive DNA - 
damage. Common to all these different forms of senescence is that they are thought to 
depend on activation of DDR. For example, oncogene activation has been shown to lead to 
DNA replication stress, DSBs and activation of DDR, although there are some claims that 
this is not a universal requirement for OIS (Efeyan et al., 2009). If the DDR is inhibited, the 
senescence barrier is lost and tumors become larger and more invasive (Bartkova et al., 
2006). The interplay between DDR and senescence may even be more complex. It has been 
suggested that tumor cells that have overcome the senescence barrier exploit senescence 
induced heterochromatin changes to dampen further DDR and apoptosis (Di Micco et al., 
2011).  
1.2. Prostate carcinogenesis 
1.2.1. Prostate tissue structure and function 
Prostate is the largest accessory gland of the male reproductive system. It is located at the 
base of the urinary bladder and surrounds prostatic urethra (Moore and Dalley, 2006, 
illustrated in Figure 2.) and consists of glandular structures and a surrounding 
fibromuscular stroma. Its main function is to secrete fluid rich in nutrients that support 
semen, and together with seminal vesicles prostate is responsible for producing the bulk of 
the seminal fluid. Prostate gland can be divided into several anatomically distinct zones, 
namely peripheral, central, transition and periurethral zones, which differ in their disease 
profiles (McNeal, 1981). Benign prostatic hyperplasia mostly affects the periurethral 
region, while approximately 70 % of prostate cancer develops in the peripheral and around 
25 % in the transition zone (McNeal, 1981; McNeal et al., 1988). The zones differ slightly 
in their morphology. Ducts in the peripheral zone are relatively small and surrounded 
loosely by smooth muscle fibers, while the central zone is characterised by large acini 
separated by closely - packed smooth muscle fibers (Laczko et al., 2005). 
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Figure 2. Schematic illustration of the anatomy of human prostate and seminal vesicles, sagittal 
view.  
The prostate epithelium consist of two major compartments and five related cell types: 
basal, luminal and neuroendocrine cells and transit amplifying and stem cells, all of which 
can be identified by specific markers (Peehl, 2005) and Figure 3A. Basal cell compartment 
consists of small, flattened basal cells that express cytokeratins 5 and 14, very low levels of 
androgen receptor (AR) and do not express prostate specific antigen (PSA) (Garraway et 
al., 2003). They can also be identified by expression of p63 (Barbieri and Pietenpol, 2006; 
Di Como et al., 2002). The exact function of basal cells is unknown, but they are 
replication - proficient and are thought to be able to differentiate into luminal cells. 
Luminal compartment consists of terminally differentiated columnar luminal cells that line 
the glands and are responsible for the secretory functions of prostate. The ratio of basal to 
luminal cells in prostate is approximately 1:3 (Laczko et al., 2005). The luminal cells 
express high levels of AR, PSA, prostate – specific acid phosphatase (PAP) and 
cytokeratins 8 and 18 and are androgen - dependent for survival (Garraway et al., 2003). 
More than 85 % of them are also positive for cell cycle inhibitor protein p27 (De Marzo et 
al., 1998). Neuroendocrine cells are rare, constituting 1 - 2 % of prostate cells, and their 
function is unknown. They are scattered around in the epithelium and can be detected by 
their expression of chromogranin A or neuron - specific enolase (Laczko et al., 2005; 
Peehl, 2005). Transit amplifying cells have mostly been characterized in primary cell 
cultures of prostate epithelium (Garraway et al., 2003; Peehl, 2005; Uzgare et al., 2004). 
They are thought to represent an intermediate cell type that is not entirely basal or luminal 
cell, but still more differentiated than prostate stem cell. Transit amplifying cells express 
both basal and luminal type cytokeratins and have a limited proliferative capacity. Prostate 
stem cells are androgen – independent, have limitless self - renewal capacity and able to 
reconstitute all the other epithelial cell types (De Marzo et al., 2010). 
 
 
 
 
18 
 
 
Figure 3. Prostate (A) and seminal vesicle (B) epithelial structure and cell types. See text for 
details. 
1.2.2. Prostate carcinogenesis 
Prostate cancer is one of the most frequent types of cancer in men with around 4500 new 
cases diagnosed in Finland and more than 200 000 in USA every year. Prostate cancer 
incidence has risen steadily, most likely due to enhanced screening and lifestyle changes. 
Several risk factors for prostate cancer have been described. The most significant ones 
include aging, family history and ethnic background as well as exposure to androgens 
(Abate - Shen and Shen, 2000; Shen and Abate - Shen, 2010). It has been suggested that 
prostate cancer is driven by inflammation caused by viral and bacterial infections, hormonal 
changes, dietary carcinogens, urine reflux and physical trauma (De Marzo et al., 2007).  
Pathological, epidemiological and cytogenic evidence suggest that prostate cancer 
develops progressively from early low - grade prostatic intraepithelial neoplasia (PIN) –
lesions through high grade PIN into full - blown cancer (Joshua et al., 2008), and in 75 % 
of cases it is multifocal (Ruijter et al., 1996). The natural course of the disease is usually 
slow, and refraining from radical treatment options is justified. However, in a significant 
 
 
 
 
19 
number of patients (ca. 15 – 20 % of cases according to Finnish Cancer Registry), prostate 
cancer is more aggressive, even fatal. A considerable amount of evidence suggests that 
multiple anatomically separate primary tumors arise independently (Bostwick et al., 1998; 
Cheng et al., 1998; Macintosh et al., 1998; Mehra et al., 2007; Ruijter et al., 1999), but 
most lethal metastases of prostate cancer are derived from the same primary lesion and are 
of monoclonal origin (Liu et al., 2009). Despite years of efforts in finding specific markers 
for the aggressive, metastatic disease form (Kumar - Sinha and Chinnaiyan, 2003; Seligson 
et al., 2005; Varambally et al., 2005), it is still challenging to differentiate the patients that 
do benefit from aggressive treatment. 
Most prostate cancer cases are adenocarcinomas of epithelial origin, but which epithelial 
cell type is the cell of origin for prostate tumors has not been established conclusively. 
There is evidence to support that targeting of both basal or luminal cells can give rise to 
prostate tumors (De Marzo et al., 2010; Moscatelli and Wilson, 2010). Luminal cells have 
been likely candidates as a cell - of origin, as prostate tumor cells have morphological and 
biochemical similarities to luminal cells and the basal cell layer is missing in prostate 
tumors. This was recently supported by Wang et al. (2009), who showed that deletion of 
phosphatase and tensin homologue (PTEN) in castration resistant luminal stem cells leads 
to overexpression of phosphorylated AKT and to a rapid formation of high - grade PIN and 
carcinomas in mice. There is some evidence that a similar luminal stem cell exist in human 
prostate (Zhao et al., 2010), but its role in human tumorigenesis has not been addressed. On 
the other hand, transformation of basal cells could also lead to prostate tumorigenesis. First, 
isolation of primary epithelial cells has shown that basal cells have better proliferative 
capacity in cell culture (Huper and Marks, 2007; Peehl, 2005). Second, paracrine 
stimulation of FGF signaling, ERG overexpression and AKT activation resulted in PIN and 
prostate cancer in murine basal cell transplanted in vivo with urogenital sinus mesenchyme, 
while luminal cells failed to respond (Lawson et al., 2010). Another group showed that 
benign primary human prostate epithelial cells expressing basal cell markers keratin 5 and 
p63 could reconstitute prostate glandular structure when transplanted subcutaneously into 
immunodeficient mice with murine urogenital sinus mesenchyme and Matrigel, while 
keratin 18 positive luminal cells could not. More importantly, only basal cells were able to 
form PIN - lesions and adenocarcinomas after induced AKT, ERG and AR expression in 
this model, indicating that prostate tumors can develop from basal cells (Goldstein et al., 
2010).  
1.2.3. Genetic changes in prostate tumors 
Characterization of genetic and epigenetic changes in prostate cancer cells has produced 
many important advances in understanding the steps leading to tumorigenesis. As prostate 
tumors are quite heterogeneous, it is likely that there are several combinations of genetic 
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events that can lead to prostate cancer, but some common themes have been described 
(Joshua et al., 2008; Taichman et al., 2007). Early events that lead to disturbed regulation 
of proliferation and decreased apoptosis include downregulation of CDKN1B expression 
(encodes the cell cycle inhibitor p27), loss of PTEN (activates AKT – pathway), 
deregulation of the TGF - beta pathway and loss of NKX3.1. These are followed by loss of 
GSTP1, an enzyme that reduces carcinogenic burden (Hayes et al., 2005), activation of 
MYC and telomerase enzyme and loss of retinoblastoma (RB), which affects cell cycle 
progression. At metastatic prostate cancer stage, p53 is lost in 50 % of tumors, and 
androgen signaling pathways are further disturbed by AR amplification or mutations 
(Reviewed in De Marzo et al., 2007; Joshua et al., 2008; Shen and Abate - Shen, 2010; 
Taichman et al., 2007). 
Chromosomal rearrangements are known to occur in leukemias, lymphomas and 
sarcomas (Nambiar and Raghavan, 2011). There are two main types of rearrangements: 
either a proto - oncogene and a regulatory region of another gene are fused together, which 
leads to altered gene expression or fusion of two genes produces a novel fusion protein. 
These fusions are thought to arise a consequence of faulty repair of DSBs, and were 
thought to be infrequent in solid tumors. In 2005, a recurrent gene fusion was identified 
between androgen regulated TMPRSS2 gene and a family of ETS - transcription factors 
(ERG, ETS variant gene 1 (ETV1), ETS variant gene 4 (ETV4)) (Tomlins et al., 2005). 
TMPRSS2-ERG was shown to be one of the most common gene fusions detected in solid 
tumors, found in approximately 50 % of prostate cancer (Kumar - Sinha et al., 2008). The 
role of ERG overexpression in regulating prostate tumorigenesis has been extensively 
studied. In mice ERG - overexpression is sufficient to induce PIN - type of changes, but it 
humans it seems to contribute to the transition from PIN lesions to prostate cancer (Carver 
et al., 2009; Klezovitch et al., 2008; Tomlins et al., 2008; Zong et al., 2009). ERG 
overexpression has been reported to disrupt AR signaling and activate a H3K27 
methyltransferase enhancer of zeste homolog 2 (EZH2) (Yu et al., 2010). Both these 
changes abrogate lineage - specific differentiation of prostate cell and promote oncogenic, 
stem cell like properties (Yu et al., 2010). 
The range of genomic alterations in prostate cancer has become more complete by recent 
reports using advanced technologies. Extensive, integrated analysis of 218 primary and 
metastatic prostate tumors by focused exon sequencing, copy-number alteration and mRNA 
expression studies revealed new potential oncogenes (NCOA2) and tumor suppressors 
(FOXP1, RYBP and SHQ1) and indicated that copy-number alterations define clusters of 
low- and high-risk disease (Taylor et al., 2010). It also revealed that although single 
mutations in known oncogenes and tumor suppressor genes (e.g. PIK3CA, KRAS, BRAF 
and TP53) are rare, RB signaling pathway driving G1/S progression as well as PI3K and 
RAS/RAF signaling pathways are altered in a significant number of primary and metastatic 
prostate tumors (Taylor et al., 2010). In order to characterize the full spectrum of somatic 
alterations in prostate cancer, Berger et al. (2011) sequenced the complete genome of seven 
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prostate tumors. They discovered that overall mutation rate in prostate cancer was similar to 
acute myeloid leukemia and breast cancer, but 7 - 15 fold lower than in small cell lung 
cancer or melanoma (Berger et al., 2011). The rate of genomic rearrangements with median 
of 90 alterations per genome was similar to what has been described in breast cancer. 
Interestingly, they also described a novel pattern of complex chain of balanced 
translocations (illustrated in Figure 4.), and suggested that these might arise from 
erroneous repair of DSBs of genes migrated into same transcription factories or located in 
the same chromatin compartment. Formation of these inter- and intrachromosomal fusions 
of multiple genes would deregulate multiple pathways at once and thus efficiently drive 
tumorigenesis (Berger et al., 2011).  
 
Figure 4. Complex fusions detected in prostate cancer. Balanced translocations are formed 
between four inter - and intrachromosomal loci. Modified from Berger et al., 2011. 
1.2.4. How chromosomal translocations are formed in prostate 
The importance of chromosomal translocations in prostate tumorigenesis is recognized, and 
there are some clues on how the fusions, especially between TMPRSS2 - ERG arise. In 
1996, Kuettel et al. (1996) published that SV40 T – immortalized human fetal prostate 
epithelial cells can be transformed and formed tumors in athymic mice after a cumulative 
dose of 30 Gy was reached by repeated exposure to ionizing radiation (IR). The tumors did 
not harbor point mutations in p53 or ras, but showed numerous chromosomal defects and 
especially chromosome 3 and 8 translocations (Kuettel et al., 1996). The undisputed role of 
androgen exposure in formation of neoplasms of prostate, the fact that TMPRSS2 and ERG 
genes are located 3 Mb apart on the same chromosome and a report indicating that estrogen 
induced rapid chromosomal movements inspired several groups to investigate whether AR 
signaling would contribute to gene rearrangements in prostate cancer. First, 
dihydrotestosterone (DHT) treatment of LNCaP prostate cancer cells was shown to induce 
proximity between TMPRSS2 and ERG loci in an AR - dependent manner, and a 
subsequent treatment of the cells with IR lead to the appearance of the fusion in clonally 
expanded cells (Mani et al., 2009). Second, DHT and IR were shown to induce 
chromosomal translocations synergistically in LNCaPs by AR - induced chromosomal 
interactions and DSBs possibly generated by activation - induced cytidine deaminase (AID) 
and LINE - 1 ORF2 endonuclease (Lin et al., 2009). Knockdown of components of NHEJ-
pathway (DNA - PK, Ku70, Ku80, LIG4 and XRCC4) was shown to attenuate, and 
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removal of ATM or HR proteins (RAD51, XRCC2, RAD52, RAD54 and BRCA1) to 
enhance the induction of the TMPRSS2 - ERG-fusions, suggesting that NHEJ is the major 
repair pathway responsible for generating these translocations (Lin et al., 2009). Third, 
induction of AR target gene expression after androgen stimulation was shown to require 
TOP2B (Haffner et al., 2010). Moreover, DHT treatment of LNCaP and LAPC4 cells led to 
the recruitment of AR and TOP2B to regulatory regions of AR target genes and was shown 
to cause TOP2B-dependent recombinogenic DSBs without extrinsic genotoxic stress 
(Haffner et al., 2010). Fourth, prolonged androgen stimulation at supra - physiological 
levels has been confirmed to induce TMPRSS2 – ERG - fusions in immortalized benign 
prostate epithelial cells, although at a much slower rate (5 months vs. 24 hours) than in 
malignant cells (Bastus et al., 2010). 
1.3. Primary seminal vesicle carcinomas are extremely rare 
1.3.1. Seminal vesicle tissue structure and function 
Seminal vesicles are a paired, elongated structure located superior to prostate gland (Moore 
and Dalley, 2006). They secrete alkaline fluid with sucrose and a coagulating agent into the 
ejaculatory duct. The seminal vesicle arteries and veins are derived form the inferior vesical 
and middle rectal blood vessels, as are the blood vessels of prostate (Moore and Dalley, 
2006). Interestingly, seminal vesicles and the central zone of prostate are embryologically 
derived from the Wolffian duct and only rarely harbour neoplasms, while the rest of the 
prostate is derived from the urogenital sinus (McNeal, 1981). 
The epithelial structure of seminal vesicles is similar to prostate with a few important 
exceptions (Figure 3B). The basal cell layer in seminal vesicles is discontinuous, the basal 
cells are more rounded than in prostate and do not express cytokeratin 14 (Laczko et al., 
2005). There are no neuroendocrine cells in the seminal vesicles, and secretory cells of 
seminal vesicles are not positive for PSA or PAP (Laczko et al., 2005). On the other hand, 
AR is expressed in their secretory and stromal cells and both tissues are androgen 
dependent (Laczko et al., 2005).  
1.3.2. Cancer of the seminal vesicles 
True seminal vesicle carcinomas are extremely rare. There were no registered primary 
seminal vesicle carcinomas (SVCA) in the Finnish Cancer registry during 1953 – 2008 
(Risto Sankila, personal communication) and a little more than 50 cases have been 
described in the medical literature worldwide (Thiel and Effert, 2002). Several diagnostic 
criteria have been published to distinguish SVCAs from other, more prevalent tumor types 
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of the anatomical region. First, the tumor should be macro - and microscopically verified 
carcinoma that is localized exclusively or mainly to seminal vesicles, there must not be 
other primary carcinomas in the body and the tumor should preferentially be a papillary 
adenocarcinoma (Dalgaard and Giertzen, 1956). Second, SVCA can be differentiated from 
prostatic adenocarcinomas, bladder transitional cell carcinomas, rectal and bladder 
adenocarcinomas and carcinomas of mullerian duct origin by immunohistochemical 
analysis of five markers: they have been reported to be negative for PSA, PAP and CK 20 
and positive for CK7 and CA - 125 (Ormsby et al., 2000). Third, prostate adenocarcinomas 
have been reported to be negative for mucin 6 that is widely expressed in seminal vesicle 
epithelium (Leroy et al., 2003).  
As they are such an oddity, it is possible that in some rare occasions seminal vesicle 
tumors are misdiagnosed as one of the secondary tumors originating from prostate, rectum 
or urinary tract, a much more likely option when tumor growth is detected in seminal 
vesicles. Nevertheless, there is clearly a significant difference in cancer incidence between 
prostate and seminal vesicle tissue, which has prompted De Marzo et al. (2007) to list this 
organ selectivity as one of the enigmas that need to be explained in order for us to 
understand why prostate cancer is so prevalent. Only few reports have attempted to answer 
this question. Profiling of gene expression from 11 normal prostate and seven seminal 
vesicle frozen tissue samples indentified 215 candidate cancer genes that were more highly 
expressed in seminal vesicles, and a subsequent combining of this dataset to another of 
1235 genes expressed at lower level in prostate cancer narrowed the number down to a 
group of 32 genes (Thompson et al., 2008). The identified 32 genes (listed in Table 1.) did 
not affect a single cellular outcome but rather various cellular processes including 
membrane transport, xenobiotic transport and protease function, and the biologic role of 
eight genes was unknown (Thompson et al., 2008). Another report recounted that the 
transgenic adenocarcinoma of mouse prostate (TRAMP) – mice that express SV40 large T 
antigen under the prostate specific rat probasin promoter, also develop seminal vesicle 
tumors (Yeh et al., 2009), which indicates that p53 and Rb pathways may have a role in 
protecting seminal vesicles from tumorigenesis. 
Table 1. List of candidate genes protecting seminal vesicles from carcinogenesis (modified 
from Thompson et al., 2008). The listed genes were expressed at higher levels in 
seminal vesicle tissue than in prostate. 
Gene 
symbol 
Chromosome 
location 
Gene name Biologic process Additional 
references 
ABCC3  17q22 ATP-binding 
cassette, sub-
family C, member 
3 
Membrane 
transport 
 
ABCG2 4q22 ATP-binding Membrane  
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cassette, sub-
family G, member 
2 
transport 
C8orf13 8p23.1a Chromosome 8 
open reading frame 
Unknown, 
associates with 
several 
autoimmune 
diseases 
Hom et al., 2008, 
Ito et al., 2010a, 
Ito et al., 2010b, 
Torres et al., 
2010, Nordmark 
et al., 2011 
CAPN6 Xq23 Calpain 6 Protease activity  
CLU 8p21 Clusterin Possible role in 
apoptosis 
 
CRABP2 1q21.3a Cellular retinoic 
acid binding 
protein 
Retinoic acid 
signaling 
 
CXCL6 4q13.3 Chemokine (C-X-
C motif) ligand 
Chemotaxis  
DNAJC15 13q14.1 DnaJ homolog, 
subfamily C, 
member 
Unknown, loss may 
confer drug 
resistance 
Shridhar et al., 
2001  
Witham et al., 
2008 
EST 12q12 Expressed 
sequence tag 
(AA703625) 
Unknown  
EST 4p15.32 Expressed 
sequence tag 
(N90470) 
Unknown  
FADS2 11q12.2 Fatty acid 
desaturase 2 
Fatty acid 
metabolism 
 
FAM46A 6q14 Family with 
sequence similarity 
46, member A 
Unknown, may 
affect 5-FU 
efficacy in breast 
cancer 
Tsao et al., 2010 
FLJ26998 10p13 cDNA FLJ26998 Unknown  
GATA3 10p15 GATA binding 
protein 3 
Lineage-specific 
transcription 
 
GLIS3 9p24.2 GLIS family zinc 
finger 3 
Transcriptional 
regulation 
 
GOLSYN 8q23.2 Golgi-localized 
protein 
Vesicular transport  
GPRC5B 16p12 G protein-coupled 
receptor, family C, 
group 5, member B 
Unknown  
GSTM2 1p13.3 Glutathione S- Xenobiotic  
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transferase M2 metabolism 
GSTP1 11q13 Glutathione S-
transferase pi 
Xenobiotic 
metabolism 
 
KRT7 12q13.13 Keratin 7 Cytoskeletal 
filament 
 
LMO3 12p12.3 LIM domain only 
3 
Unknown, may 
interact with p53 
and reduce its 
transcriptional 
activity 
Larsen et al., 
2010 
ME1 6q12 Malic enzyme 1, 
NADP(?)-
dependent, 
cytosolic 
Fatty acid 
metabolism 
 
PDK4 7q21.3 Pyruvate 
dehydrogenase 
kinase, isozyme 4 
Sugar metabolism 
 
 
PFKFB3 10p15.1 6-Phosphofructo-2-
kinase/fructose-
2,6-biphosphatase 
3 
Sugar metabolism 
 
 
PTGS2 1q25 Prostaglandin-
endoperoxide 
synthase 2 
Prostaglandin 
synthesis 
 
PYGL 14q21-q22 Phosphorylase, 
glycogen 
Glycogen 
metabolism 
 
SERPINA5 14q32.1 Serpin peptidase 
inhibitor, clade A, 
member 5 
Coagulation  
SLFN11 17q12 Schlafen family 
member 11 
Unknown  
SLPI 20q12a Secretory 
leukocyte 
peptidase inhibitor 
Immune response  
SNCG 10q23 Synuclein, gamma Neurofilament 
network 
 
SPINT1 15q15.1 Serine peptidase 
inhibitor, Kunitz 
type 1 
Protease inhibitor  
TGFBR3 1p33-p32 Transforming 
growth factor, beta 
receptor III 
TGFbeta signaling  
aProstate cancer susceptibility locus 
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2. DNA damage response (DDR) 
DDR is a common nominator for the activation of multiple pathways after DNA damage. 
DDR includes detection of the damage and activation of the proper DNA repair pathway, 
activation of cell cycle checkpoints or decision to enter into apoptosis or senescence. In 
2005, two groundbreaking papers described that DDR pathways are activated in 
premalignant lesions, and suggested that they form a barrier against tumorigenesis 
(Bartkova et al., 2005; Gorgoulis et al., 2005). They showed that ATM - pathway is 
constitutively more active in premalignant lesions than in cancer of urinary bladder, breast, 
colon, lung and skin. The also showed that overexpression of oncogenes that promote 
replication leads to DDR activation in cancer cell lines. DDR has been confirmed to be 
active also during prostate tumorigenesis. A study investigating markers of ATM - pathway 
activation, ATMSer1981, γH2AX and checkpoint kinase 2 (CHK2) Thr68 phosphorylation, of 
35 primary prostate cancer and PIN specimens reported that DDR is activated in 
premalignant PIN lesions more strongly than in cancer (Fan et al., 2006).  
The underlying cause of the DDR in premalignant lesions is somewhat debated. It has 
been proposed that activated oncogenes induce aberrant proliferation and stalling and 
collapse of replication forks that lead to DSBs especially in common fragile cites 
(Halazonetis et al., 2008). In premalignant lesions functional DDR activated by DSBs 
would be able to induce apoptosis or senescence, thus limiting cancer development. In time, 
constant DNA replication stress could cause genomic instability, inactivate tumor 
suppressor pathways like ATM and p53 and promote tumorigenesis (Halazonetis et al., 
2008). 
2.1. ATM – pathway 
Ataxia – telangiectasia mutated (ATM) - pathway is essential in orchestrating cellular 
responses to DSBs. Activation of this pathway has been shown to regulate many stress 
responses, including DNA damage repair mechanisms, cell cycle checkpoints, cellular 
proliferation, radiation sensitivity, apoptosis and senescence (Derheimer and Kastan, 2010). 
An outline of some of the most relevant ATM - mediated responses after DSBs is presented 
in Figure 5. 
 
 
 
 
27 
 
Figure 5. ATM - pathway activation after DSBs. ATM - kinase activates signaling pathways that 
regulate DNA damage repair, cell cycle checkpoints and chromatin condensation. 
See text for details. M,R,N=MRN complex, p=phosphorylation, Ub=ubiquitylation, 
H2B= histone 2B 
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2.1.1. ATM 
ATM is one of the key molecules mobilizing cellular response to DSBs. It is a nuclear 
serine - threonine kinase, which activates other DDR proteins by phosphorylating their 
serine or threonine residues within SQ or TQ motifs (Derheimer and Kastan, 2010). ATM 
belongs to the family of phosphatidylinositol - 3 - kinase related protein kinases (PIKKs) 
together with ATM and Rad3 related protein kinase (ATR) and DNA dependent protein 
kinase catalytic subunit (DNA - PKcs) mammalian target of rapamycin (mTOR), 
suppressor of morphogenesis in genitalia (SMG - 1) and transformation / transcription 
domain - associated protein (TRRAP) (Lempiainen and Halazonetis, 2009). PIKKs are 
large serine/threonine kinases involved in signaling after cellular stress. DNA - PK is 
activated by DSBs similarly to ATM, while ATR responds to UV damage, single - stranded 
DNA and replication stress (Cimprich and Cortez, 2008; Lempiainen and Halazonetis, 
2009). ATM is expressed ubiquitously, also in normal prostate tissue and prostate cancer 
(Angele et al., 2004). 
Loss of ATM function causes genomic instability. Atm deficient embryonic stem cells 
are hypersensitive to IR, Atm null mouse embryo fibroblasts (MEFs) have been shown to 
have defective cell cycle checkpoint activation and p53 stabilization after IR and Atm null 
thymocytes are more resistant to IR - induced apoptosis than normal mouse thymocytes 
(Xu and Baltimore, 1996) (Westphal et al., 1997). Hereditary loss or inactivation of ATM 
protein function in humans causes a syndrome called A - T. A - T is a recessive autosomal 
disease that is characterized by a progressive neurological disorder due to cerebellar 
degeneration (Taylor and Byrd, 2005). The clinical features include ataxia of both upper 
and lower limbs detectable usually by the age of two, immunodeficiency, growth 
retardation and telangiectasia (dilated blood vessels that are most noticeable on eyes of the 
patients). A - T patients are highly sensitive to IR and have a high risk of developing 
lymphoid tumors with typical chromosomal translocations. Heterozygous patients are 
usually devoid of these symptoms, but may have slightly increased risk of developing 
breast cancer (Taylor and Byrd, 2005). Atm - deficient mice display similar symptoms as A 
- T - patients. The Atm - / - mice are retarded in growth, have neurological dysfunction, 
infertility and defects in T - lymphocyte maturation (Barlow et al., 1996; Elson et al., 1996; 
Xu et al., 1996). They are extremely sensitive to IR and develop thymic lymphomas at an 
early stage (Barlow et al., 1996; Elson et al., 1996). ATM protein function is not essential 
for development or viability of these mice (or A - T patients), but the affected tissues 
indicate that ATM has an important role in maintaining genomic integrity in mitotic, post - 
mitotic and meiotic cells. 
In unstressed cells ATM exists in an inactive, homodimerized state (Bakkenist and 
Kastan, 2003). After the formation of DSBs, ATM is activated by intermolecular 
autophosphorylation on serine 1981 and dissociation from the dimers (Bakkenist and 
Kastan, 2003; Berkovich et al., 2007 and Figure 5a). The autophosphorylation of ATM is a 
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rapid process and has been show to occur even in the absence of DBS by treatments 
altering chromatin structure, so it is likely that the initial signal activating ATM is a change 
in the chromatin (Bakkenist and Kastan, 2003). Activated ATM is recruited to the sites of 
DSBs forming foci that can be visualized by fluorescence microscopy (Andegeko et al., 
2001). ATM kinase activity, ATMSer1981 autophosphorylation and functional Nijmegen 
breakage syndrome protein 1 (Nbs1) protein are required for ATM to accumulate into these 
DNA damage foci and to initiate DSB repair (Bakkenist and Kastan, 2003; Berkovich et 
al., 2007; Falck et al., 2005; Wu et al., 2000), although the absolute requirement of serine 
1981 phosphorylation has been questioned in mouse models (Pellegrini et al., 2006) and in 
vitro studies (Lee and Paull, 2005). Nbs1 is a part of a complex with meiotic recombination 
11 (Mre11) and Rad50 (MRN complex) that accumulates to DSB prior to ATM and is 
involved in early processing of the break. The presence of MRN complex is required for 
full ATM kinase activity, retention of ATM at the damaged site and phosphorylation of 
several downstream targets (Falck et al., 2005; Lee and Paull, 2005; Uziel et al., 2003). 
ATM is required for effective DSB repair and it is thought to carry out this function by 
phosphorylating a vast number of DSB signaling proteins (Figure 5b). Some of the ATM 
target proteins accumulate at the sites of DSBs in a spatially and temporally controlled 
manner (Bekker - Jensen et al., 2005), while others remain dispersed in the nucleoplasm 
(Bekker - Jensen et al., 2006). Among the many ATM target proteins that accumulate into 
sites of DSB and mediate various aspects of DNA repair are Nbs1 (Wu et al., 2000), 
Mre11, H2AX (Burma et al., 2001; Stiff et al., 2004), mediator of DNA - damage 
checkpoint 1 (MDC1) (Lou et al., 2006), p53 - binding protein - 1 (53BP1) (Anderson et 
al., 2001; Rappold et al., 2001; Xia et al., 2001), BRCA1 (Cortez et al., 1999) and KRAB - 
associated protein (KAP - 1) (Ziv et al., 2006). The role of some of these proteins in DSB 
signaling will be discussed in more detail in the chapters below. The huge complex of 
proteins in DNA damage foci is thought to modify chromatin structure and concentrate 
DNA repair factors into the damaged site so that efficient DSB repair can be accomplished.  
Several chromatin modifications have been linked to activation of ATM by DSBs. One 
of the most well - known, phosphorylation of histone variant H2AX on serine 139 
(γH2AX), will be discussed in more detail below. Activation of the ATM - pathway has 
been shown to lead to the removal of histone 2B (H2B) and accumulation of XRCC4 in 
cells synchronized into G1 (Berkovich et al., 2007). Another target of ATM, nuclear 
phosphoprotein KAP - 1 is known as a repressor of transcription, that is associated with 
heterochromatin formation. Around 10 – 25 % of DSBs in nondividing cells are defectively 
repaired if ATM signaling is lost, and this occurs specifically in the regions of 
heterochromatin (Goodarzi et al., 2008; Riballo et al., 2004). It has been shown that ATM - 
dependent KAP - 1 phosphorylation on serine 824 mediates heterochromatin relaxation, 
increases cell survival after DSBs and is thought to make damaged DNA more accessible 
for repair factors (Goodarzi et al., 2008; Ziv et al., 2006). Recently, ATM was shown to 
phosphorylate heterodimeric E3 ubiquitin ligase complex formed by RNF20 and RNF40, 
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which induced monoubiquitylation of histone H2B in an ATM - dependent manner (Moyal 
et al., 2011). This modification has been associated with transcription elongation in 
unstressed cells, but after DSBs it was required for optimal repair of DSBs by NHEJ and 
HR (Moyal et al., 2011).  
Presence of DSBs needs to be signalled to the cell cycle checkpoint machinery in order 
for cells to avoid DNA replication and mitosis with damaged chromosomes. ATM 
signaling has been shown to affect all the cell cycle checkpoints, which will be discussed in 
more detail in the chapter on cell cycle checkpoints. Further roles of ATM include telomere 
maintenance (Celli and de Lange, 2005; Karlseder et al., 2004) and insulin signaling 
(Schneider et al., 2006; Yang and Kastan, 2000). 
2.1.2. H2AX 
DNA in cell nucleus is packed around histone proteins to form the organized structure of 
chromatin. The core unit of chromatin, the nucleosome, consists of four types of core 
histone proteins, H2A, H2B, H3 and H4 and a linker histone H1 acting as a bridge between 
the nucleosomes. All the core histones are covalently modified by a wide variety of 
enzymes to regulate processes like transcription, DNA repair or apoptosis (Jenuwein and 
Allis, 2001). These covalent modifications can either alter the state of chromatin 
compaction or binding of other proteins to DNA. All the core histones are covalently 
modified in response to DSBs and these modifications have an integral role in DDR and 
DSB repair (Downs et al., 2007).  
Histone H2AX is a variant form of the core histone H2A. It has been estimated that 
H2AX constitutes 2 – 20 % of the total H2A pool and is found on average in every fifth 
nucleosome (Bonner et al., 2008). Most core histones are synthesized during S - phase of 
the cell cycle, but H2AX can also be transcribed in a replication - independent manner 
(Mannironi et al., 1989; Wu et al., 1982). It has an evolutionary conserved C - terminal tail 
that protrudes out of the globular structure of histones and thus is accessible to modifying 
proteins (Dickey et al., 2009). Since 1998, when DSBs were reported to induce H2AX 
phosphorylation on serine 139 (Rogakou et al., 1998) and specific antibodies could be used 
to detect this γH2AX in DNA damage foci (Rogakou et al., 1999), γH2AX has been widely 
used as a sensitive marker for DSBs (Bonner et al., 2008; Dickey et al., 2009 and Figure 
6.). Although the bulk of attention has been focused on γH2AX, there are at least two other 
phosphorylation sites on H2AX (Cook et al., 2009; Pantazis and Bonner, 1981; Xiao et al., 
2009). 
Hereditary syndromes with genomic instability involving mutations of H2AX gene have 
not been described to date, but the physiological consequences of H2AX loss have been 
investigated in H2AX deficient mice (Celeste et al., 2002). H2AX null mice share many 
but not all features of Atm - / - mice. They are viable, growth retarded, immune deficient, 
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sensitive to irradiation, and the males are infertile (Celeste et al., 2002).  H2AX -/- MEFs 
grow poorly in culture and embryonic stem cells (ES), MEFs and T - cells exhibit a high 
number of chromosomal aberrations, although contrary to Atm -/- cells, they do not have 
explicit defects in cell cycle checkpoints (Bassing et al., 2002; Celeste et al., 2002). The 
recruitment of Nbs1, 53BP1 and Brca1 to IR induced DNA damage foci is impaired in 
H2AX -/- ES cells, B - cells and fibroblasts (Bassing et al., 2002; Celeste et al., 2002). 
Moreover, deletion of a single H2AX allele has been show to increase the number of 
chromosomal translocations and to enhance tumorigenesis in a p53 null background in 
mice, indicating that maintenance of sufficient levels of H2AX are required for achieving 
optimal DSB repair (Bassing et al., 2003; Celeste et al., 2003a). ATM and H2AX have 
significantly overlapping functions in DSB repair, especially in G1 phase of the cell cycle, 
as combined Atm -/- H2AX -/- deficiency leads to embryonic lethality and severe genomic 
instability in ES cells, MEFs and mature B and T cells (Zha et al., 2008). The ATM 
independent functions of H2AX may include repair of postreplication DNA damage (Zha et 
al., 2008). 
H2AX is phosphorylated in response to many types of DNA damaging agents 
(Takahashi and Ohnishi, 2005), and the primary kinases carrying out the γ - 
phosphorylation are ATM, ATR and DNA–PK. Distinct types of DNA lesions activate the 
three PIKKs (Burma et al., 2001; Park et al., 2003; Stiff et al., 2004; Ward and Chen, 2001; 
Ward et al., 2004). ATR is sensitive to UV lesions and replication stress and induces a 
more diffuse pan - nuclear H2AX phosphorylation, while AMT and DNA - PK detect 
DSBs and result in a focal staining pattern of γH2AX (Marti et al., 2006). Although both 
ATM and DNA - PK are able to phosphorylate H2AX redundantly in response to DSBs 
(Stiff et al., 2004), it seems that ATM is the major kinase phosphorylating γH2AX after IR 
(Burma et al., 2001) and DNA - PK, as a part of the NHEJ - pathway, is more involved in 
the repair of the lesions (Koike et al., 2008; Mahaney et al., 2009). There also may be some 
tissue specificity between ATM and DNA - PK in respect of γH2AX (Koike et al., 2008).  
The role of H2AX in DSB repair is mainly mediated by its γ - phosphorylation. γH2AX 
foci serve as platforms for the recruitment of several DNA repair and chromatin 
remodelling factors (e.g. Nbs1, Rad50, 53BP1 and Brca1) needed for the DSB signaling 
(Celeste et al., 2003b; Fernandez - Capetillo et al., 2003; Paull et al., 2000). Also, γH2AX 
is reported to be involved in the G2/M cell cycle checkpoint activation after low amounts of 
DNA damage (Fernandez - Capetillo et al., 2002), in recruitment of cohesins to promote 
sister chromatid - dependent recombinatiorial repair (Xie et al., 2004), and in prevention of 
dissociated of broken DNA ends (Bassing and Alt, 2004). Besides the rapid γH2AX 
induction, successful DSB repair seems also to require timely removal of the γH2AX 
signal. Several phosphatases, including PP2A and PP4 have been implicated in the 
dephosphorylation of γH2AX (Chowdhury et al., 2005; Chowdhury et al., 2008). 
There are two phosphorylation events of H2AX that have a role in apoptosis. First, 
γH2AX has long been known to be induced by various treatments causing apoptosis and to 
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coincide with the initiation of DNA fragmentation, an ultimate form of DSBs (Rogakou et 
al., 2000). The apoptotic γH2AX signal is pan - nuclear and intensive, and may be mediated 
by other kinases than DNA - PK or ATM (Mukherjee et al., 2006). One of the kinases 
phosphorylating γH2AX after apoptotic dose of UV damage has been reported to be c - Jun 
N - terminal kinase (JNK) (de Feraudy et al., 2010; Lu et al., 2006), and γH2AX under 
these circumstances was required for efficient DNA ladder formation (Lu et al., 2006). 
Second, H2AX phosphorylation on another residue, tyrosine 142 has been shown to 
regulate DNA repair, apoptosis and survival decisions (Lukas and Bartek, 2009). 
Tyrosine142 phosphorylation levels are maintained constant in unstressed cells by tyrosine 
kinase WSTF, which has previously been implicated in nucleosome mobilization and DNA 
replication (Xiao et al., 2009). After DNA damage, the levels of tyrosine 142 decrease 
concomitantly with increased γH2AX, but without prior WSTF activity and tyrosine 142 
phosphorylation, γH2AX cannot be maintained and ATM and MDC1 recruitment to DSBs 
are compromised (Xiao et al., 2009). The phosphatases that remove tyrosine 142 
phosphorylation from H2AX after DNA damage have been identified as EYA1 and EYA3 
that are known to regulate organ development. If tyrosine 142 is removed by EYA, γH2AX 
is able to recruit MDC1 and promote DNA damage repair. If both phosphorylations are 
present, MDC1 accumulation to DSBs is inhibited and JNK1 is able to bind to tyrosine 142 
and drive apoptosis (Cook et al., 2009). How this apoptotic switch is orchestrated in human 
cells still needs more investigation, as we currently do not know what determines the 
balance between the serine 139 and tyrosine 142 phosphorylations after DSBs. 
H2AX deficient mice have indicated that H2AX is important in tumor suppression and 
maintenance of genomic integrity (Bassing et al., 2002; Bassing et al., 2003; Celeste et al., 
2002; Celeste et al., 2003a). Clearly H2AX has a role in mediating recruitment of DSB 
signaling and repair proteins onto damaged chromatin, and it may be involved in deciding 
between DNA damage repair and apoptosis. How important these H2AX functions are for 
the tumor suppressor function of H2AX has not been fully addressed, and it remains to be 
determined in which cell types, phases of cell cycle and under what circumstances H2AX 
function cannot be overlooked. 
2.1.3. 53BP1 
53BP1 was first described through its ability to bind to tumor suppressor p53, and it was 
suggested to enhance p53 - mediated transcription (Iwabuchi et al., 1994; Iwabuchi et al., 
1998). Then it was recognized as a part of DSB signaling complex that is phosphorylated 
by ATM and accumulates onto chromatin at sites of DSBs (Anderson et al., 2001; Rappold 
et al., 2001; Schultz et al., 2000; Xia et al., 2001), and started to attract more attention.  
Generation of 53BP1 – deficient mice indicated that it is required for genomic integrity 
and has a role in tumor suppression (Morales et al., 2003; Ward et al., 2003). Similarly to 
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Atm and H2AX deficient mice, 53BP1 null mice were born at expected rates, were growth 
retarded, had immunodeficiencies and were sensitive to irradiation, chromosomal 
abnormalities and thymic lymphomas. However, contrary to Atm -/- mice, they had only 
very mild cell cycle checkpoint defects and were fertile, which indicates that 53BP1 is not 
essential in meiosis (Morales et al., 2003; Ward et al., 2003). Further, the number of 
spontaneous chromosomal aberrations is lower in 53BP1 -/- cells and the increase in tumor 
incidence only mild, which findings are compatible with the role of 53BP1 downstream of 
ATM. Loss of p53 combined with 53BP1 deficiency greatly increases lymphomagenesis in 
mice and the number of chromosomal abnormalities, but conflicting reports have been 
published on whether there is dosage - dependency (haploinsufficiency) in 53BP1 -
mediated tumor suppression (Morales et al., 2006; Ward et al., 2005). 
 
 
Figure 6. γH2AX induction and 53BP1 relocalization from nucleoplasm into DNA damage foci 
after IR in U2OS osteosarcoma cell line. 
In unstressed cells, 53BP1 is nucleoplasmic in G1, accumulates into foci in S, and is 
expressed at very low levels in G2/M phase (Morales et al., 2003) and Figure 6. As it was 
known to interact with a well - known cell cycle regulator, p53, 53BP1 was also suspected 
to play a role in checkpoint activation after DNA damage. Depletion of 53BP1 from human 
cancer cell lines or mouse B - cells and MEFs was shown to result in defective intra - S - 
phase and G2/M checkpoints with low (2 - 3 Gy) doses of IR (Fernandez - Capetillo et al., 
2002; Wang et al., 2002) and to affect p53 stability and Chk2 phosphorylation (Wang et al., 
2002). On the other hand, others have reported that the S - and G/M checkpoint defects in 
mouse embryonic cells are slight and could rather be caused by impaired DSB repair than a 
bona fide cell cycle checkpoint defect (Ward et al., 2003).  
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53BP1 protein has no characterized enzymatic activity that could explain its role in DSB 
repair. Instead, it is considered to act as a recruitment platform for other DDR proteins 
(FitzGerald et al., 2009). Accumulation and retention of 53PB1 in DSB foci is complex and 
requires the activity of several ubiquitylating enzymes and methylated histones. First, 
γH2AX has been shown to be dispensable for the initial recruitment of 53BP1 to the DSB, 
but required for its sustained retention at the sites (Celeste et al., 2003b). Second, MDC1 
seems to be required either directly (Eliezer et al., 2009) or indirectly via other post - 
translational modifications. Phosphorylated MDC1 interacts with γH2AX and a E3 
ubiquitin ligase RNF8 (Mailand et al., 2007), which forms a complex with E2 conjugating 
enzyme UBC13 and a candidate assembly factor HERC2 (Bekker - Jensen et al., 2010) and 
ubiquitylates H2A. This ubiquitinylated H2A then interacts with another ubiquitin ligase 
RNF168 that together with UBC13 amplifies the lysine - 63 ubiquitin conjugation at DSBs 
(Doil et al., 2009). The MDC1 - RNF8 - RNF168 - HERC2 –mediated polyubiquitylation 
seems to be essential for successful retention of 53BP1 at DSBs. Third, 53BP1 has also 
been reported to interact with methylated histone residues. Structural analyses on the 
tandem tudor domain of 53BP1 indicated that histone H3 methylated on lysine 79 (H3 - 
K79me) is able to bind to 53BP1 (Huyen et al., 2004). H3 - K79me is mediated by a 
methyltransferase DOT1L, and downregulation of DOT1L decreases the number of 53BP1 
foci after IR. As H3 - K79 methylation levels do not change after IR, it has been suggested 
that DSBs alter nucleosome stacking so that this histone mark is exposed supporting 53BP1 
binding (Huyen et al., 2004). On the other hand, another report rejected that H3 - K79me 
would have a significant biological role in recruitment of 53BP1 and instead presented that 
direct interaction between 53BP1 and histone H4 lysine 20 dimethylation (H4 - K20me2) is 
required for 53BP1 retention at DSBs (Botuyan et al., 2006). Regulation of H4 - K20me2 
has recently been connected to ATM activity, as H4 - K20me2 levels were reportedly 
locally induced by a new histone methyltransferase MMSET, another ATM - target that is 
recruited to DSBs in an γH2AX - MDC1 – dependent manner (Pei et al., 2011). 
However 53BP1 may be recruited to DSBs, it has a role in protecting chromosomal 
integrity in response to IR. Recent reports indicate that 53BP1 function seems to be 
required especially in NHEJ and repair of heterochromatin DSBs. As NHEJ and HR both 
repair DSB, inhibition of one leads to increased need of the other one. Depletion of 53BP1 
or preventing its interaction with H4 - K20me2 was shown to increase HR levels in an 
XRCC4 dependent manner (Xie et al., 2007). Interestingly, this 53BP1  - mediated NHEJ 
was reported to be independent of H2AX (Xie et al., 2007). Another study indicated that 
53BP1 and its interaction with H4 - K20me2 are required for optimal NHEJ of unprotected 
telomeres (Dimitrova et al., 2008). They suggested that 53BP1 increases chromatin 
mobility that is needed to bring the damaged DNA ends into close proximity (Dimitrova et 
al., 2008). 53BP1 has also been linked to the ATM - dependent KAP - 1 phosphorylation 
that is essential for repair of DSBs in heterochromatin regions (Noon et al., 2010). 
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2.1.4. DSB signaling network involves a complex array of post - translational 
modifications 
The cellular signaling occurring after DSBs is complex and involves many other post - 
translational modifications and proteins than discussed above. Merely the number of 
phosphorylation events induced by DSBs is astounding. Extensive characterization of IR - 
induced phosphorylations on SQ - TQ –motifs, which are common in substrates for ATM 
(Kastan and Lim, 2000) and ATR, identified around 900 phosphorylation events in over 
700 proteins, most of which had not been previously described (Matsuoka et al., 2007). 
Based on their biological function, 420 proteins out of the 700 could be divided into various 
categories, including highly relevant groups of DNA replication, recombination and repair 
(46 genes), cell cycle (72 genes), mRNA transcription (101 genes) and chromatin 
remodelling (22 genes). ATM was estimated to regulate 70 % of the substrates. Another 
group investigating both ATM - dependent and - independent phosphorylation events 
occurring after DSBs could identify 411 damage - induced phosphorylations and 342 
dephosphorylations on 394 proteins (Bensimon et al., 2010). Approximately 60 % of these 
were ATM - dependent, supporting the role of ATM as the main transducer of DSB 
response. Among the other kinases involved were ATR, DNA - PK, cyclin - dependent 
kinase 1 (CDK1), cyclin - dependent kinase 2 (CDK2) and casein kinase 2 (CK2).  
CDK1 and CDK2 have an important role in cell cycle checkpoints, and they will be 
discussed below. The role of CK2 in DSB repair is not characterized in detail, but it has 
been connected to the ever - growing group of DSB – induced chromatin modifiers (Lukas 
and Bartek, 2008). CK2 has been reported to be required for phosphorylation of 
heterochromatin protein 1 - β (HP1 - β) after DSBs (Ayoub et al., 2008). In unstressed cells 
HP1 - β is bound to histone H3 methylated on lysine 9 (H3K9me). Phosphorylation of HP1 
- β after DNA damage releases it from chromatin, and this mobilization of HP1 - β enables 
efficient phosphorylation of γH2AX (Ayoub et al., 2008). In addition, CK2 has been shown 
to phosphorylate H4 serine 1 after DNA damage (Cheung et al., 2005) and facilitate repair 
of single strand breaks (Loizou et al., 2004). 
Phosphorylation is only one of the many possible post - translational modifications 
occurring after DNA damage. As discussed above, ubiquitylation events may be equally 
important. Ubiquitylation requires activity of three different types of enzymes: E1 ubiquitin 
- activating enzyme activates ubiquitin so that it can be transferred to its target proteins by 
E2 ubiquitin - conjugating enzymes and E3 ubiquitin - ligases (Chen and Sun, 2009). 
Several DSB signaling proteins, including RNF8, RNF168, Ubc13 and BRCA1, are E2 and 
E3 enzymes (Messick and Greenberg, 2009; Panier and Durocher, 2009). Respectively, 
their less studied counteracting enzymes, deubiquitinating enzymes (DUBs) are able to 
modify DSB signaling (Nakada et al., 2010). There are also reports indicating that 
acetylation (Fischle, 2009), methylation and sumoylation events (Bartek and Hodny, 2010; 
Galanty et al., 2009; Morris et al., 2009) are closely involved in DSB repair. It still remains 
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unresolved how all these signaling routes are coordinated (Ciccia and Elledge, 2010), but 
chromatin structure and the organization of the genome have an effect (Misteli and 
Soutoglou, 2009). We are still far from understanding the complete picture of DDR. 
2.2. p53, the guardian of the genome 
p53 tumor suppressor is essential for maintenance of genomic integrity. It has been under 
rigorous investigation for more than 30 years, and its role in tumor suppression has proven 
to be rather complex (Vousden and Prives, 2009; Zilfou and Lowe, 2009). It is generally 
accepted that p53 is a transcription factor and regulates multiple processes implicated in 
cancer, including cell cycle checkpoints, cellular senescence, autophagy and apoptosis 
(Zilfou and Lowe, 2009). It is activated by various stress signals, including DNA damage, 
oncogene activation, ribosomal stress, loss of cell - cell contacts and hypoxia (Horn and 
Vousden, 2007). Considering that p53 is mutated in approximately 50 % of human tumors 
and in a large proportion of the rest p53 pathway is inactivated by another means, p53 has 
been an attractive target for new cancer drug development (Brown et al., 2009). 
Germ - line p53 mutations result in a familial cancer syndrome called Li - Fraumeni that 
is characterized with early - onset tumors (Malkin et al., 1990). The classical Li - Fraumeni 
component tumors are breast carcinomas, bone and soft tissue sarcomas, brain tumors, 
adrenocortical carcinomas and leukemias that account for approximately 75 % of all the 
tumors detected in Li - Fraumeni (Nichols et al., 2001). The remaining 25 % originate from 
diverse sites, but tumors of lung, stomach, ovaries, colon and rectum have been reported on 
multiple occasions. In a study listing 738 tumors of 185 Li - Fraumeni - patients and their 
first - degree relatives, prostate cancer was detected in 7 cases corresponding to 0,1 % of all 
tumors (Nichols et al., 2001). This clearly indicates that in prostate tumorigenesis p53 has a 
limited role. Similar results have been obtained from p53 null mice. They are prone to a 
wide spectrum early - onset tumors, especially to lymphomas and sarcomas (Donehower et 
al., 1992; Harvey et al., 1993). IR is able to decrease tumor latency of heterozygous but not 
p53 null mice, where spontaneous tumor rate is already high (Kemp et al., 1994). 
Due to its potent growth inhibitory effects, p53 levels in unstressed cells are kept low by 
proteosomal degradation. Under normal circumstances, two structurally related proteins 
murine double minute - 2 (Mdm2) and Mdm2 related protein (MDM4, also known as 
MdmX) are essential for suppression of p53 activity (Marine et al., 2006). Mdm2 is the 
major E3 ubiquitin ligase that ubiquitinates p53 and directs it into degradation (Haupt et al., 
1997; Honda et al., 1997; Kubbutat et al., 1997). Transcription of Mdm2 is directly 
activated by p53, and this forms a negative feedback loop that is essential for keeping p53 
activity under control. MDM4 is responsible for transcriptional repression of p53 (Marine 
and Jochemsen, 2004). A long list of other E3 ligases, including Cop1 (Dornan et al., 2004) 
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and Pirh2 (Leng et al., 2003) have been described for p53, but they are probably not as 
essential as Mdm2. 
p53 is stabilized and activated rapidly after DNA damage through a series of post - 
translational modifications that release it from its negative regulators (Lavin and Gueven, 
2006). There are more than 36 sites of p53 that can be phosphorylated, acetylated, 
methylated, ubiquitinated or sumoylated by a variety of different proteins (Kruse and Gu, 
2009). p53 is phosphorylated at least by ATM (Canman et al., 1998; Saito et al., 2002), 
ATR (Tibbetts et al., 1999), DNA - PK, JNK, CK2, checkpoint kinase 1 (CHK1) and 
CHK2 (Chehab et al., 2000), all of which are implicated in DDR. IR induces ATM 
mediated phosphorylations either directly or via CHK2 (Chehab et al., 2000) on multiple 
sites of p53 and Mdm2 (Maya et al., 2001) and destabilizes their interaction. Also MDM4 
is phosphorylated in the process.  
p53 stability and activity are further modulated by two DUBs called herpesvirus - 
associated ubiquitin - specific protease (HAUSP) and USP10. HAUSP is able to 
deubiquitinate and stabilize p53 (Li et al., 2002), but in unstressed cells it also stabilizes 
Mdm2 and Mdm4 favouring p53 degradation. ATM - mediated phosphorylation of Mdm2 
and Mdm4 lowers their affinity towards HAUSP and shifts the balance towards p53 
stabilization after IR (Meulmeester et al., 2005). USP10 is a cytoplasmic ubiquitin specific 
protease that stabilizes p53 and counteracts Mdm2 - mediated degradation (Yuan et al., 
2010). After IR, USP10 is phosphorylated by ATM, is stabilized and translocates into the 
nucleus, where it further increases p53 activity (Yuan et al., 2010). How p53 is stabilized in 
vivo in different tissues and by various forms of stress has still not been completely 
resolved (Kruse and Gu, 2009).  
p53 regulates many of its biological functions by inducing transcription of a suitable set 
of genes (Espinosa, 2008). There are at least 129 potential p53 responsive genes in the 
human genome (Riley et al., 2008) and considerable tissue and cell specificity exists in 
expression of p53 target genes both basally and after genotoxic treatments (Bouvard et al., 
2000; Butz et al., 1998; Fei et al., 2002; Komarova et al., 1997; Komarova et al., 2000). 
For example, p21 has been shown to be expressed basally in mouse small intestine, lung 
and heart, while proapoptotic BAX was expressed also in spleen, thymus and brain tissue 
(Bouvard et al., 2000). Mouse spleen and thymus showed a high induction of p21 after IR 
as did heart, lung, liver and brain. BAX was mostly activated in thymus and spleen that are 
known to be radiosensitive organs (Bouvard et al., 2000). 
There are two ways for p53 to induce apoptosis: either directly or by inducing 
transcription of proapoptotic genes. p53 can translocate into mitochondria, induce 
mitochondrial outer membrane permeabilization and release proapoptotic factors. The 
proapoptotic genes upregulated by p53 include BAX, PUMA, NOXA, p53AIP and PIG3 
(Vousden and Lu, 2002). p53 and ATM have been show to cooperate in induction of 
apoptosis in mouse thymocytes (Westphal et al., 1997). If both TP53 and Atm are deleted, 
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tumorigenesis is accelerated and the tumor spectrum is broader than with a loss of a single 
gene (Westphal et al., 1997). 
It is difficult to pinpoint the most relevant tumor suppressive function of p53, as the 
effects of p53 induction are dependent on many factors including cell type and genetic 
background (Zilfou and Lowe, 2009). Nevertheless, several mouse models have been used 
to investigate this question in a particular setting (Lozano, 2010). There are some 
indications that ATM mediated p53 activation is required (Meek, 2009). At first it was 
reported that the lack of serine 18 phosphorylation (mouse equivalent for serine 15) would 
not render mice susceptible to tumors (Chao et al., 2003), but later analysis on the mice 
indicated that they are prone to several late - onset malignancies, including lymphomas and 
sarcomas (Armata et al., 2007). Mice where both p53 serine 18 and 23 (corresponding to 
human serine 15 and 20) are changed into alanines and cannot be phosphoyrlated, develop a 
spectrum of tumors that differs from p53 -/- mice (Chao et al., 2006). A recent DNA 
sequencing study on 188 human lung adenocarcinomas revealed that ATM and p53 
mutations were mutually exclusive, suggesting that the loss of either one is sufficient to 
silence the DDR pathway (Ding et al., 2008).  
On the other hand, there are reports that indicate the opposite. It has been postulated that 
oncogenic stress stabilizes Arf by preventing its degradation and that this activates p53 - 
mediated growth arrest and mediates most of p53 tumor suppression (Chen et al., 2010; 
Martins et al., 2006), while p53 response induced by DNA damage may be of less 
importance. One study used a conditional mouse model where p53 activity can be switched 
on and off to study the role of acute DDR in suppression of IR - induced lymphomas 
(Christophorou et al., 2006). They concluded that if p53 was allowed to function 
immediately after IR, it caused widespread apoptosis of lymphoid tissues and intestinal 
epithelium, but did not succeed in reducing lymphoma incidence from p53 null mice. If p53 
activity was restored eight days after IR, the acute toxic effects were abrogated and IR - 
induced lymphomas were suppressed in an Arf - dependent manner (Christophorou et al., 
2006). p53 mediated cellular senescence has been implicated in mouse prostate 
tumorigenesis. Conditional inactivation of p53 alone did not result in prostate tumors, but 
combined loss of PTEN and p53 led to rapid carcinogenesis (Chen et al., 2005). This was 
explained by the fact that PTEN loss induced high levels of Arf, p53 and p21, and 
abrogation of p53 abolished this senescence response and allowed rapid progression of 
tumors (Chen et al., 2005). 
2.3. Cell cycle checkpoints 
DNA damage can transiently delay cell cycle progression in G1, S and G2/M phases 
through inhibition of CDK activity. The main cyclin - CDK - pairs governing the 
checkpoints are CDK2 and cyclin E for G1, CDK2 and cyclin E/A for S - phase 
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(Malumbres and Barbacid, 2009), and CDK1 and cyclin B for G2/M (Lindqvist et al., 
2009). ATM and ATR have a paramount role in launching a cascade of rapid 
phosphorylation events that leads to the inhibition of CDK/cyclin complexes and 
subsequent checkpoint activation after DNA damage (Iliakis et al., 2003). The 
phosphorylation cascade involves early DNA damage sensors (e.g. MRN complex, ATM, 
ATR), mediators (e.g. MDC1, 53BP1) and transducers (e.g. checkpoint kinase 1 (CHK1) 
and CHK2) of the signal, and effector molecules (e.g. p53, cell division cycle 25 
phosphatase (CDC25)) that modulate cellular function (Kastan and Bartek, 2004; Lobrich 
and Jeggo, 2007). ATM and CHK2 are expressed throughout the cell cycle and also in 
quiescenct or differentiated cells, while ATR and CHK1 are restricted to S - G2 - phases 
(Jones et al., 2004; Kaneko et al., 1999; Lukas et al., 2001; Matsuoka et al., 1998). In the 
following chapters the main focus is on how IR and DSB activate the G1, intra - S and 
G2/M checkpoints. 
2.3.1. G1 checkpoint 
G1 - checkpoint prevents cells with damaged DNA from progressing from G1 into S - 
phase. It is thought to be more sensitive than the G2/M checkpoint, and has been proposed 
to be the master regulator of genomic stability (Lobrich and Jeggo, 2007). There are two 
partially overlapping mechanisms that activate G1 arrest: a rapid, transient and p53 - 
independent pathway and a slower, more permanent p53 - mediated arrest that requires 
transcription of new proteins (Bartek and Lukas, 2001; Kuerbitz et al., 1992). Both are 
ATM - dependent. In the first pathway, activated ATM phosphorylates CHK2 that in turn 
phosphorylates phosphatase CDC25A. This increases the proteolytic degradation of 
CDC25A (Mailand et al., 2000) and thus prevents the removal of inhibitory threonine 14 
and tyrosine 15 phosphorylations from CDK2. The ATM - CHK2 - CDC25A - CDK2 
pathway is activated within 20 - 30 minutes after IR, and during the first hours is able to 
reduce the number of cells entering into S - phase (Deckbar et al., 2010). The second, more 
permanent G1 arrest –pathway is also initiated by ATM, which phosphorylates p53 on its 
amino terminus serine 15 (Banin et al., 1998; Canman et al., 1998). As discussed above, 
this and further modifications of negative regulators of p53, such as Mdm2, MDM4 and 
USP10, release p53 from degradation and increase its ability to transactivate gene 
expression. The key transcriptional target of p53 in G1 arrest is the CDK inhibitor p21 
(Abbas and Dutta, 2009). In some cell types, e.g. in normal human fibroblasts, IR - 
triggered long - term induction of p21 and a prolonged G1 growth arrest may be 
reminiscent of cellular senescence (Di Leonardo et al., 1994). In others, G1 arrest is not 
permanent.  
G1 checkpoint is sensitive and has been estimated to arrest cell cycle progression even 
after a single DSB (Huang et al., 1996), but it is by no means flawless. In fact, there are two 
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significant limitations to the G1 checkpoint (Deckbar et al., 2010). First, the initial CHK2 - 
dependent transient arrest does not fully abolish S - phase entry, and full G1 arrest is only 
observed several (>4) hours after IR. Second, the G1 - checkpoint is maintained 
inefficiently, as a small fraction of cells (<5 %) is able to progress into G2 with markers of 
DNA damage. Both limitations can lead to appearance of chromosomal breaks and have the 
potential to cause genomic instability. 
G1 to S - phase progression is altered in a significant number of prostate cancer cases. 
Loss of chromosome 13q and RB and CDK4 inhibitor p27 expression are both prevalent in 
prostate tumors (De Marzo et al., 1998; Abate - Shen and Shen, 2000). More recently, 
integrated oncogenomic profiling showed that the regulation of RB signaling is affected by 
mutations, copy - number alterations and expression changes of p27, cyclin E1, CDK2 and 
RB in 34 % of primary prostate tumors (Taylor et al., 2010). In addition, the DNA damage 
activated G1 checkpoint may be deregulated at least in a subset of prostate tumors, as 
germline mutations in the gene encoding CHK2 have been reported in sporadic (in 4,8 % of 
cases) and familial (3,3 – 10,8 %) prostate cancer cases (Dong et al., 2003; Seppälä et al., 
2003). At least two of these mutations, 1100delC and IVS2+1G→A reduce the levels of 
CHK2 expression (Dong et al., 2003). The role of p53 in the maintenance of the G1 
checkpoint in prostate cancer is more ambiguous. Missense mutations of TP53 are rare in 
early stages of prostate cancer, but copy - number loss is much more prevalent, detected in 
ca. 24 % of cases (Taylor et al., 2010). 
2.3.2. Intra - S - checkpoint 
Lack of intra - S - phase checkpoint activation results in radioresistant DNA synthesis 
(RDS), a feature long connected to cells derived from AT - patients (Painter, 1981). Intra - 
S - phase checkpoint is governed by ATM and ATR and shares many features with the G1 
arrest (Lukas et al., 2004). Activation of the checkpoint results in an arrest that lasts only 
for a few hours. It consists of the ATM - CHK2/ATR - CHK1 - CDC25A phosphorylation 
cascade. Phosphorylated CHK1 or CHK2 phosphorylate CDC25A on its serine 123 and 
direct it to degradation, which allows the retention of the inhibitory threonine 14 and 
tyrosine 15 phosphorylations on CDK2 (Falck et al., 2001). Inhibition of CDK2 blocks the 
loading of CDC45 onto chromatin and prevents recruitment of DNA polymerase. The 
degradation of CDC25A is already maximal 30 minutes after IR, and gradually recovers to 
basal levels in four - eight hours. Normally, DNA - synthesis is reduced by 50 % few hours 
after a dose of 10 Gy of IR (Falck et al., 2001).  
Many other proteins have been implicated in the maintenance of the intra - S - 
checkpoint but their function is not entirely clear. It is possible that the mediators of the 
DSB signaling implicated in cell cycle checkpoints including MDC1 (Goldberg et al., 
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2003), BRCA1 and 53BP1 (Wang et al., 2002), are required to amplify the signaling 
cascade to the level that is sufficient in launching the arrest. 
2.3.3. G2/M checkpoint 
G2/M checkpoint prevents mitotic entry with damaged DNA. It has been suggested to be 
less sensitive than the G1 checkpoint and to tolerate 10 or even 20 DSBs before activation 
(Deckbar et al., 2007; Lobrich and Jeggo, 2007). It is mostly p53 independent, as many 
tumor cell lines with inactivated p53 still maintain functional G2/M checkpoint. Similarly 
to the rapid activation of G1 and intra - S - arrests, G2/M checkpoint is mediated by CHK1 
and CHK2, but the pathway is somewhat more complex. In G2, both ATM - CHK2 and 
ATR - CHK1 activate the degradation of CDC25A and cytoplasmic sequestration of its 
family members CDC25B and CDC25C. This leads to inhibition of CDK1/cyclinB activity.  
2.3.4. Role of Wee1A in cell cycle checkpoints 
Wee1A tyrosine kinase phosphorylates CDK1 and CDK2 on tyrosine 15 and inhibits their 
kinase activity (Parker and Piwnica - Worms, 1992; Watanabe et al., 1995). Another, 
related kinase called Myt1 preferentially phosphorylates CDK threonine 14 residues (Liu et 
al., 1997; Mueller et al., 1995). Wee1 and Myt1 counteract the effects of CDC25 
phoshatase family members that remove these inhibitory phosphorylations (Parker and 
Piwnica - Worms, 1992). Together they all form the inner feedback loop regulating cyclin 
B – CDK1 complex activity that is important for normal cell cycle coordination as well as 
G2/M DNA damage checkpoint (Lindqvist et al., 2009).  
Wee1 is located predominantly in the nucleus (Baldin and Ducommun, 1995; McGowan 
and Russell, 1995), while CDK1 - cyclin B complex and CDC25 phosphatase family 
members can shuttle back and forth between nucleus and cytoplasm. Myt1 localizes to the 
endoplasmic reticulum and Golgi (Liu et al., 1997). Wee1 kinase activity and cellular levels 
are low in G0/G1, start to increase in S - phase and remain high until the onset of mitosis 
(Baldin and Ducommun, 1995; McGowan and Russell, 1995; Watanabe et al., 1995). 
Multiple phosphorylations regulate the rapid degradation of Wee1 at M - phase (Watanabe 
et al., 1995). First, it is a direct phosphorylation target of CDK1 itself that phosphorylates 
Wee1 on serine 123 (Watanabe et al., 2004). Second, the serine 123 phosphorylation 
enables CK2 to phosphorylate it on another serine residue, serine 121. Third, CDK1 - CK2 
double phosphorylated Wee1 is subsequently a suitable target for polo - like kinase 1 (Plk1) 
that phosphorylates serine 53 residue of Wee1 (Watanabe et al., 2005). After these three 
phosphorylation events, Wee1 is efficiently recognized by SCF - β - TrCP ubiquitin ligase 
complex and directed it into proteosomal degradation (Watanabe et al., 2004; Watanabe et 
al., 2005). Further, it has been reported that AKT is able to phosphorylate Wee1 on serine 
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642, induce Wee1 binding to 14 - 3 - 3θ and cause it to translocate into cytoplasm. Thus 
AKT could promote G2/M progression (Katayama et al., 2005). 
Both Wee1 and CDC25 are phosphorylated by CHK1 after DNA damage, and this 
activates the cell cycle checkpoint. CDC25 phosphorylation by CHK1 is thought to 
promote its interaction with 14 - 3 - 3 proteins, which leads to the retention of the complex 
in the cytoplasm. At the same time, DNA damage causes the transient 
hyperphosphorylation and stabilization of Wee1A (Raleigh and O'Connell, 2000). As 
CHK1 and Wee1 regulate the G2/M checkpoint that in many cancer cells is the major 
remaining cell cycle checkpoint, their inhibition has been considered a potential target for 
cancer therapy (Dent et al., 2011). Small molecule inhibitors of Wee1 have been reported to 
be efficient in combination treatment with IR and DNA – damaging agents in several 
cancer cell lines, including prostate cancer cell lines (Hirai et al., 2009; Hirai et al., 2010; 
Bridges et al. 2011). There are some indications that downregulation of Wee1 can abrogate 
G2 checkpoint and induce apoptosis in HeLa and breast cancer cells (Murrow et al., 2010; 
Wang et al., 2004). 
2.4. DNA damaging agents as cancer therapy 
Classical anticancer drugs can be divided into three categories: chemotherapy and IR, 
hormonal therapy and immunotherapy (Espinosa et al., 2003). Chemotherapeutic drugs can 
further divided into subgroups based on their chemical structure and mechanism of action. 
Most of them cause excessive DNA damage, activate cell cycle arrest and cell death either 
directly or after DNA replication, and thus are efficient in killing proliferating cancer cells 
(Helleday et al., 2008).  
2.4.1. Cancer treatment by radiotherapy 
Radiotherapy has long been used as a successful means of therapy in many cancer types, 
including prostate cancer (Bentzen, 2006). Its primary target is DNA. IR causes direct 
damage to the bases and the sugar - phosphate backbone (Hagen, 1994), and it is able to 
induce high number of DSBs, single - strand breaks and oxidative damage even in non - 
proliferating cells (Ciccia and Elledge, 2010). DSBs are considered the most toxic of all 
DNA lesions. It has been estimated that 1 Gy of IR causes on average 30 – 40 DSBs in a 
living cell (Lobrich et al., 1994). There is variation in how well patients respond to 
radiation therapy. This is understandable, as radiation induces gene expression of thousands 
of genes and in some there is considerable variance between individual patients (Smirnov et 
al., 2009).  
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2.4.2. Topoisomerase I and II inhibitors 
DNA topoisomerases are enzymes that resolve topological problems that are caused by 
DNA unwinding (Nitiss, 2009a). When DNA molecule is opened up to allow transcription 
or replication, local unwinding causes supercoiling elsewhere. Topoisomerase enzymes 
cause spatially and temporally controlled breaks into DNA to relieve this stress. They are 
divided into two types by their mode of action: topoisomerase I enzymes (TOP1) introduce 
single strand breaks and topoisomerase II (TOP2) induce DSBs (Champoux, 2001). 
TOP1 - inhibitors such as camptothecin (CPT) target human TOP1 enzyme (Liu et al., 
2000). CPT blocks reversibly the rejoining step in the cleavage - religation reaction and 
results in accumulation of the cleavage - complex on DNA. Combined with DNA 
replication this complex disturbs replication fork progression and causes cytotoxicity and 
DSBs in the S - phase (Furuta et al., 2003; Kurose et al., 2005). In addition, CPT may be 
cytotoxic outside of S - phase. CPT treatment prevents RNA synthesis by inhibiting 
transcription elongation, and can induce single - strand breaks and a small number of DSBs. 
It has been shown that CPT treatment results in DSBs and activation of ATM - pathway in 
post - mitotic neurons and lymphocytes via inhibition of transcription and formation of 
RNA - DNA - hybrids between open DNA and nascent RNA - transcript (Sordet et al., 
2009). It is noteworthy that this induction of DSBs and ATM activation in post - mitotic 
cells required considerable drug concentrations (Sordet et al., 2009). 
There are two types of TOP2 enzymes in mammalian cells: TOP2α and TOP2β (Nitiss, 
2009a). TOP2α is essential for separating replicated chromosomes in all cells, while 
TOP2β is dispensable in some cell types. TOP2 - enzymes work as homodimers, where 
each subunit breaks one DNA strand. The enzyme is able to carry out the cutting without 
losing the energy of the phosphodiester bond in DNA, so that resealing of the cleavage does 
not require high - energy cofactors. Interestingly, TOP2β - mediated DSBs have been 
shown to be required for activation of gene transcription by 17β - estradiol - stimulated 
estrogen receptor (Ju et al., 2006) as well as AR (Haffner et al., 2010). 
TOP2 - inhibitors such as doxorubicin and etoposide induce DSBs by trapping the TOP2 
- enzyme in the DNA cleaving complex (Nitiss, 2009b). When TOP2 - inhibition is caused 
by the covalent trapping of the enzyme onto DNA, as is the case with doxorubicin and 
etoposide, the drugs are termed TOP2 poisons. TOP2 poisons do not require DNA 
replication to induce DSBs like some other drugs, e.g. cisplatin (Frankenberg - Schwager et 
al., 2005). Doxorubicin may trap TOP2 by its intercalation into DNA - molecule. Etoposide 
differs from doxorubicin by the fact that it does not intercalate into DNA. Its effect is 
supposedly mediated by protein - DNA - interactions (Nitiss, 2009b). As TOP2 enzyme 
activity is essential for DSB induction by TOP2 - inhibitors, it is not surprising that 
resistance to TOP2 - inhibitors such as doxorubicin has been associated with a decrease in 
the protein expression levels (Burgess et al., 2008). 
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2.5. DNA damage response in primary and terminally differentiated cells 
The groundwork on DDR has largely been carried out in cancer cell lines, but there are a 
few reports investigating how various primary cells of mouse or human origin respond to 
IR. Especially mouse ES cells, MEFs, thymocytes and leukocytes have been used in many 
prominent studies and have been sited elsewhere in the text. Some key studies on radiation 
responses of various primary cell types are listed in Table 2.  
p53 activation, apoptosis and cell cycle checkpoints have been studied in primary mouse 
cells and irradiated mice. p53 mediated apoptosis after IR was first characterized in mouse 
thymocytes (Clarke et al., 1993; Lowe et al., 1993), and IR induced G1 arrest in MEFs 
(Kastan et al., 1992). Subsequent whole mice irradiation studies have clearly demonstrated 
that cell types differ in their radiation responses. For example, both epidermal and hair 
follicular cells of mouse skin stabilize p53, but epidermal cells respond with p21 - mediated 
growth arrest while hair follicular cells undergo apoptosis (Song and Lambert, 1999). The 
cellular outcome after DNA damage does not only depend on the cell type but also on the 
type of the damaging agent. For instance, p53 in mouse primary hepatocytes is stabilized 
after UV but not IR (Bellamy et al., 1997), and doxorubicin and IR, but not cisplatin are 
able to activate p53 dependent G1 arrest in MEFs (Attardi et al., 2004). 
There are some reports on how human primary cells respond to IR. One of the first 
observations was that normal bone marrow progenitor cells induce p53 at low levels and 
are G1 proficient (Kastan et al., 1991), which was followed by the notion that IR induces 
p53 dependent G1 arrest in normal human fibroblasts derived from foreskin or embryonic 
lung or skin (Di Leonardo et al., 1994; Kuerbitz et al., 1992). Then it was reported that, 
surprisingly, normal human prostate epithelial cells (HPECs) are unable to stabilize p53, 
p21 or activate G1 checkpoint while prostate stromal cells exhibit both responses (Girinsky 
et al., 1995). Similar results were described using bronchial epithelial cells and lung 
fibroblast (Gadbois and Lehnert, 1997) and human keratinocytes (Flatt et al., 1998). 
Further, when human mammary epithelial cells (HMECs) were reported to lack p53 and 
p21 stabilization and G1 arrest after IR (Meyer et al., 1999), it seemed that the lack of p53 - 
mediated G1 arrest was a common theme of human epithelial cells. It is noteworthy that 
cell culture environment may promote growth of only one subtype of epithelial cells, as 
discussed in the chapter on prostate tumorigenesis, and this may have influenced the DDR 
studies carried out in primary cells. When HMECs were first sorted into basal and luminal 
cells using specific markers, and then cultured separately in optimized media, it turned out 
that IR can induce p53 and p21 transiently in basal cells without a strong cell cycle 
checkpoint activation (Huper and Marks, 2007). More interestingly, luminal cells were able 
to induce p53 and p21 in a more prolonged manner, arrested S - phase entry and 
accumulated in G2/M. 
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Table 2. Radiation responses of benign primary cells. 
Cell 
Tissue of 
origin Species Dose p53 Response Reference 
Bronchial 
epithelial cells 
Lung 
 
Human 
 
2 Gy 
 
p53 
- 
Transient G1 
and G2 
Gadbois et al., 
1997 
Bone marrow 
progenitor cells 
Bone 
marrow 
 
Human 
 
 
~ 0 - 
4 Gy 
+ G1 and G2 
arrest 
Kastan et al., 
1991 
Fibroblasts 
 
Connective 
tissue Human 
0 - 6 
Gy 
+ G1 arrest DiLeonardo et 
al., 1994 
HMEC 
 
Breast 
 
Human 
 
4 Gy p53 
- 
No G1, G2 
arrest + 
Meyer et al., 
1999 
HMEC Basal 
 
Breast 
 
Human 
 
5 Gy p53 
+ 2 
h 
Transient G2 Huper et al., 
2007 
HMEC 
Luminal 
Breast 
 
Human 
 
5 Gy p53 
+ 2 - 
24 h 
Prolonged G2 
arrest 
Huper et al., 
2007 
HPECs Prostate Human 
6 Gy p53 
- 
No G1 Girinsky et al., 
1995 
Keratinocytes 
 
Skin 
 
Human 
 
8 Gy p53 
+/- 
No G1, G2 
arrest + 
Flatt et al., 
1998 
       
       
Hepatocytes Liver Mouse 15 
Gy 
UVC 
10 
J/m2 
p53 
– 
 
p53 
+ 
Transactivation 
– 
Transact. + 
Bellamy et al., 
1997 
MEFs Connective 
tissue 
Mouse 5 Gy p53 
+ 
G1 and G2 
arrest 
Attardi et al., 
2004 
Thymocytes Thymus Mouse 0 - 20 
Gy 
p53 
+ 
Apoptosis Lowe et al., 
1993, Clarke et 
al., 1993 
 
Terminal differentiation of some cell types can be induced in cell culture environment, 
and these models have been used to study DDR (listed in Table 3.). ATM - pathway, and to 
some extent p53 are activated in terminally differentiated, postmitotic cells of different 
origins after DSBs. First, neocarzinostatin (radiomimetic drug) treatment has been shown to 
activate ATM - pathway in human neurons (Biton et al., 2007). Human embryonic stem 
cells and human neural stem cells from cerebral cortex were allowed to differentiate into 
mature neurons and were treated with neocarzinostatin. The induction of ATMS1981, 
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phosphorylation of serine 824 of KAP1, γH2AX, serine 15 phosphorylation of p53 and 
phosphorylation of threonine 68 of Chk2 in these cells clearly indicated that the ATM – 
mediated DSB response is activated in postmitotic cells. The response was shown to be 
primarily ATM - dependent, as concomitant use of ATM - inhibitor KU - 55933 or ATM 
depletion via shRNA abrogated the phosphorylation of the target proteins (Biton et al., 
2007). Second, ATM autophosphorylation, γH2AX induction, recruitment of Mre11 and 
Nbs1 and CHK2 activation have been shown to occur equally after IR in proliferating 
myoblast and terminally differentiated myotubes (Latella et al., 2004). Further, p53 was not 
phosphorylated on serine 15, stabilized or transcriptionally active in myotubes after IR, 
while doxorubicin treatment did activate p53 and apoptosis in them (Latella et al., 2004). 
Third, it is possible that terminal differentiation enhances some forms of DNA repair. In 
cell culture, mouse adipocytes were shown to repair DSBs more rapidly than preadipocytes, 
and this was associated with increased levels of DNA - PKcs activity (Meulle et al., 2008). 
Inhibition of DNA - PK decreased repair efficiency only in differentiated apipocytes 
(Meulle et al., 2008). Fourth, sometimes it is possible to analyze terminally differentiated 
cells directly out of patients, without long - term culturing artefacts. Löbrich et al. collected 
lymphocytes of 23 individual patients undergoing computed tomography (CT) examination 
of thorax and/or abdomen and studied formation and repair of DSBs after low doses of IR 
(ca. 100 – 1500 mGy*cm, roughly equivalent to 20 mGy) (Lobrich et al., 2005). They 
investigated the γH2AX - levels of isolated lymphocytes either directly after the 
radiodiagnostic imaging or after a period of in vitro – culturing, and could show that this 
kind of an approach could be used to study DSB induction and repair in vivo as well as aid 
in optimizing radiation therapy doses and in identification of radiosensitive, repair - 
compromised patients.  
Table 3. DNA damage response in terminally differentiated cells. 
Cell Tissue of 
Origin 
Species Dose p53 DDR 
response 
Reference 
Adipocytes 
 
 
 
Adipose 
tissue 
 
 
Human/ 
Mouse 
 
 
IR 2 Gy 
CLγ1 
- Enhanced 
NHEJ, DNA 
- PKcs + 
Meulle et 
al., 2008 
Lymphocytes 
 
Blood 
 
Human 
 
~20 
mGy 
- γH2AX + Löbrich et 
al., 2007 
Myoblasts  
 
Muscle 
 
Human/ 
Mouse 
IR 10 
Gy 
p53 + 
Ser15 
+ 
ATM - 
pathway + 
Latella et 
al., 2004 
Myotubes 
 
Muscle 
 
Human/ 
Mouse 
IR 10 
Gy 
p53 – 
Ser15 - 
ATM - 
pathway + 
Latella et 
al., 2004 
Neurons Embryonic Human NCS p53- ATM - Biton et al., 
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stem cells 
 
 
 
100 - 
200 
ng/ml 
Ser15 
+ 
pathway + 2007 
Neurons Neural stem 
cells 
Human NCS 
100 - 
200 
ng/ml 
- ATM - 
pathway + 
Biton et al., 
2007 
 
3. Organotypic Models in Cancer Biology 
Different approaches have been used to set up new models to study various aspects of 
tumorigenesis and DDR in human tissues without disruption of the original tissue structure. 
These organotypic models have several advantages to standard cell culture techniques, as 
they enable the study of differentiated cell types that can be difficult or impossible to 
maintain in standard cell culture, conserve cell - cell contacts and heterotopic interactions 
between them and the supporting extracellular matrix that have been shown to modulate 
cell responses to stress. In addition, as practical mice models are, there are some 
limitations. First, there are considerable anatomical differences between mice and men in 
some organs. For example, mouse prostate has four paired, elongated lobes without a 
surrounding capsule, which does not entirely correspond to the human globular gland 
(Pienta et al., 2008). Second, most transgenic prostate cancer mice models develop only 
hyperplasia and PIN or demonstrate rapid progression into poorly differentiated cancer. 
Third, due to the species difference, mouse models are not optimal for preventive or 
therapeutic discoveries (Pienta et al., 2008). 
3.1. Set up of organotypic models   
Isolated cells can be directed into forming tissue like structures. Epithelial tissue stem cells 
are able to differentiate into multiple cell types and when implanted into mice together with 
supporting stromal cells, they can reconstitute the tissue structure. 3D culture systems are 
usually based on culturing of epithelial cells on Matrigel or other collagenous support that 
mimics extracellular matrix. This results in small glandlike structures that contain cells 
expressing several different cell type markers (Debnath et al., 2003). A recent report 
indicated that normal primary human epithelial cells of epidermis, oropharynx, esophagus 
and cervix can be transferred onto a section of devitalized human acellular dermis 
complemented with stromal fibroblast, and they form a stratified, differentiated epithelium 
and regenerated stromal architecture. Use of transformed epithelial cells expressing 
oncogenic RAS or CDK4 resulted in invasion through basement membrane. This 3D 
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organotypic neoplasia model was suitable for testing of several small molecule inhibitors of 
signaling pathways, including mitogen - activated protein kinase (MAPK) and PI3K, as 
well as gene expression studies (Ridky et al., 2010). 
Ex vivo – tissue culture models are based on culturing of thin slices of tissue in an 
optimized medium in culture dishes outside of human/rodent body.  The method has been 
used since 1920s, especially in studies investigating metabolism of tissues and 
neurophysiology and –pharmacology. An important technical advance was published in 
1980, when Krumdieck et al described their new instrument for the preparation of tissue 
slices (Krumdieck et al., 1980). The Krumdieck tissue slicer caused little damage to tissue 
architecture and had been used to prepare slices of rat liver, brain, spleen, kidney, heart, 
skin and adipose tissue (Krumdieck et al., 1980). Since then, similar set - up has been 
confirmed to be feasible for various benign human and rodent tissues and tumor types, 
including human brain (temporal lobe cortex and white matter) (Nitsch et al., 2000), rat 
enterorhinal - hippocampal brain sections and human glioblastoma tumors (Merz et al., 
2010), tumorous and non - tumorous human liver (Kern et al., 2006), tumor xenografts of 
human ovarian cancer cell lines, human primary ovarian tumors and human liver (Kirby et 
al., 2004), human fallopian tube epithelium (Levanon et al., 2010), human colon, lung and 
prostate carcinomas (Vaira et al., 2010), breast cancer (van der Kuip et al., 2006) and rat 
small intestine and colon (de Kanter et al., 2005). 
Direct culturing of tissue fragments is possible, if the tissue consistency does not allow 
more precise slicing. At least fragments of human cervical tissue (Collins et al., 2000), 
human testis (Roulet et al., 2006) and human breast (Huper and Marks, 2007) have been 
used. If a more prolonged tissue culture time is required, the ex vivo - tissue slices or tissue 
fragments can be implanted subcutaneously or under the renal capsule of 
immunocompromised mice, which supports growth of vasculature. 
3.2. Prostate organotypic models 
Of the different approaches presented above, most have been set up of prostate tissue. 
Human embryonic stem cells grafted together with mouse urogenital sinus mesenchyme or 
rat seminal vesicle mesenchyme under the renal capsule of adult severe combined 
immunodeficiency (SCID) mice has been shown to mature into benign human prostate 
tissue, that expresses markers for basal (p63, high - molecular weight cytokeratins), luminal 
(AR and PSA), neuroendocrine (chromogranin A) and stromal cells (α - smooth muscle 
actin, α - SMA) within 8  - 12 weeks (Taylor et al., 2006). Similarly, primary human 
prostate cancer cells isolated from Gleason grade 8 to 9 prostate cancer and further 
immortalized with transduction of exogenous telomerase have been shown to reconstitute 
the original tumor when combined with rat embryonic mesenchyme and grafted under the 
renal capsule of male SCID mice (Gu et al., 2007). Furthermore, it has been shown that 
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with careful selection of prostate stem cell markers, it is possible to generate functional 
prostate tissue from a single adult murine prostate stem cell (Leong et al., 2008; Wang et 
al., 2009) 
Three - dimensional culture models of prostate tissue have been successfully established. 
Human prostate epithelial cells immortalized with telomerase expression form spheroids on 
Matrigel and differentiate into basal and luminal cells (Kogan et al., 2006). SV40 T antigen 
- immortalized human prostatic epithelial cells (BPH - 1) grown on Matrigel have been 
shown to form prostatospheres that mimic the polarized glandular structure of prostate, as 
did their tumorigenic subline (Chu et al., 2009). This 3D - model was then successfully 
applied to studying the role of androgen signaling and PI3K - pathway in epithelial - 
mesenchymal transition. On the other hand, HPV16 E6/E7 –immortalized or human 
telomerase reverse transcriptase –immortalized, non - tumorigenic prostatic epithelial cell 
lines did not undergo similar differentiation process under the same circumstances (Chu et 
al., 2009). 
Ex vivo – tissue culture models of prostate have been shown to be applicable to short - 
term experimentation. Bläuer et al cultured benign prostate slices of 300 µm in a serum and 
growth factor free medium supplemented with DHT for seven days, and based on cell - 
type specific markers cytokeratin 18 and 14, AR, PSA, prostate acid phosphatase (PAP) 
and von Willebrand factor (endothelial cell marker) showed that major cell types remain 
viable (Blauer et al., 2008). It is possible to combine the benefits of ex vivo – tissue culture 
and xenografting. Subcutaneous implantation of small (2 - 3 mm x 1 - 2 mm) pieces of 
benign prostate or prostate cancer into the flanks of athymic nude mice has been reported to 
extend the viability time of the tissue pieces into 1 month (Gray et al., 2004). Implantation 
of thin slices of benign human prostate tissue or primary adenocarcinomas under the renal 
capsule of immunodeficient mice was reported to enable the slices to remain viable and to 
display characteristic histology and expression of cell - type specific markers for at least 
three months (Zhao et al., 2010). A considerable amount of the vasculature of the grafts 
was lined with human endothelial cells in this model (Zhao et al., 2010). 
In the stem cell based models, prostate tissue is derived from a limited number of human 
prostate cells, so it is possible that genetic changes acquired early in the development 
process in mice have enriched into the tissue, and although the microenvironment under the 
renal capsules of immunocompromised mice supports the growth and viability of human 
prostatic tissue, it may not fully recapitulate all the interactions of the surrounding tissue 
environment of human prostate. In these xenograft models prostate tissue can be 
maintained for several months and are suited for studying the effects of vasculature and 
immunosystem. 
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3.3. DNA damage response in human organotypic models 
Most studies investigating DDR have used cancer cell lines, mouse models and standard 
immunohistochemistry (IHC) techniques, but some work has been carried out in human 
organotypic models. 
Huper et al. (2007) used human breast tissue to study p53 induction after IR. They 
cultured breast tissue fragments of one patient overnight, treated them with 5 Gy of IR and 
incubated for 2 or 24 hours. The fragments were then frozen, sectioned and analyzed with 
IHC. The histology of the tissue fragments appeared normal and apoptosis was low. Two 
hours after IR, p53 induction was evident only in basal cells, but 24 hours after IR it was 
primarily detected in the luminal compartment. Similarly, H2AX phosphorylation was 
reportedly removed more rapidly from the basal cell compartment, while luminal cells 
expressed a more prolonged response (Huper and Marks, 2007). Another, a more extensive 
study on human breast tissue fragments used mouse xenografting, and analyzed the p53 
pathway activation and γH2AX responses of 10 patients four days after implantation 
(Coates et al., 2010). The percentage of apoptotic cells increased from 0,14 % to 4 % 
already four hours after 5 Gy. p53 was stabilized and phosphorylated on serines 15 and 392 
in breast epithelium in a dose dependent manner after IR, while the stromal responses were 
minimal. p21 stabilization was more pronounced in basal cells. Surprisingly, γH2AX foci 
were detected only in the epithelial cells, and they were stronger in epithelium surrounded 
by adipocyte - rich stroma than by fibroblast - rich stroma (Coates et al., 2010). 
Levanon et al. (2010) set up two new ex vivo - models of human fallopian tube 
epithelium and used them to study early DDR activation after IR treatment in the two 
epithelial cell types of fallopian tubes, ciliated and secretory cells. First, they collected 
benign fallopian tube specimens from surgical procedures, minced and digested with 
protease and DNase treatments and cultured the cell isolates on the air - liquid interface of 
polyester membrane. These cultures were shown to contain both cell types and could be 
maintained for several weeks, and interestingly, when these ex vivo – cell cultures were 
treated with IR, ATMSer1981 phosphorylation and γH2AX inductions were more pronounced 
in the secretory cells that had proliferative capacity. Second, they used fresh, whole 
fallopian tube fragments to confirm that induction of γH2AX, CHK2 and ATMSer1981 
phosphorylation and stabilization of p53 were more pronounced in the secretory cells than 
in the terminally differentiated, quiescent ciliated epithelial cells (Levanon et al., 2010). 
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Aims of the study 
Eukaryotic cells have evolved multiple pathways to detect and repair various forms of 
DNA damage to protect their genomes from accumulating genetic aberrations, the driving 
force in tumorigenesis. Characterization of these DDR pathways has successfully been 
carried out in cancer cell lines and mouse models, but they do not take into account the 
effects of cell differentiation and signaling from other cell types and extracellular matrix 
present in adult human tissues.   
This study was aimed at studying how normal human epithelial cells of two organs of 
the male reproductive system, prostate and seminal vesicle, recognize and respond to 
exogenous DNA damage during active replication and in quiescent, terminally 
differentiated state, and to look for factors that could explain the major difference in their 
susceptibility to tumorigenesis. 
 
The specific aims were to: 
1. investigate which DNA damage recognition pathways are activated by various 
forms of genotoxic and cellular stress factors in benign human prostate tissue 
2. study whether the three main cell types of adult human prostate differ in their DNA 
damage responses 
3. determine the cell cycle checkpoint proficiency of human primary epithelial cells 
4. to compare DNA damage responses in prostate and seminal vesicles 
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Materials and methods 
The materials and methods used in the study have been described in detail in the original 
publications (I - III). A list and a short description of the most relevant materials and 
methods are provided below. 
1. Materials 
1.1. Patient material (I, II, III) 
Patient material used in this study includes ex vivo – cultured live tissue samples and 
isolated primary epithelial cells of prostate and seminal vesicle, as well as standard paraffin 
embedded tissue material. Ex vivo - and primary cell material was collected from patients 
undergoing radical prostatectomy or cystectomy due to prostate or bladder cancer with 
informed consent of the patients and the permission of the Ethics Committee, Department 
of Surgery of Helsinki University Central Hospital. 
1.2. Antibodies (I, II, III) 
All primary antibodies were purchased from commercial sources listed below (Table 4.). 
The fluorescent Alexa secondary antibodies were ordered from Molecular Probes and the 
biotinylated or horseradish peroxidase – conjugated secondary antibodies from Dako. 
Table 4. Antibodies 
Antigen Clone Manufacturer Used in 
5 – Bromo – deoxy -
uridine 
 Sigma-Aldrich 
Amersham Pharmacia 
I 
II 
53BP1  Novus Biologicals I, III 
α - SMA  Sigma-Aldrich I, III 
β - tubulin  BD Biosciences II 
Phosphorylated 
AKT 
 Cell Signaling Unpublished 
Androgen receptor  Biocare Medical I, III 
ATMSer1981  Cell Signaling I, III 
Cdc25A F - 6 Santa Cruz II 
Cdk2 M2 Santa Cruz II 
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Cdk1/2 - Tyr15  Cell Signaling 
Calbiochem 
II 
II 
Cleaved caspase - 3 5A1E Cell Signaling III 
Cytokeratin 5 and 14  Imgenex I, III 
ERG  Epitomics III 
GAPDH  Europa Bioproducts I, II, III 
H2AX  Novus Biologicals 
Cell Signaling 
I, III 
I, III 
γH2AX Clone JBW301 
20E3 
pSer139 
Upstate Biotecnology 
Cell Signaling 
Epitomics 
I, II, III 
I, 
I, III 
Ki67 MIB - 1 Dako I, III 
Mucin - 6 MUC - 6 Novocastra III 
p21 12D1 
C - 19 
6B6 
Cell Signaling 
Santa Cruz 
BD Biosciences 
I, III 
II 
II 
p27 p27/Kip1 BD Biosciences 
Epitomics 
Santa Cruz 
I 
I 
II 
p53 DO - 7 
7F5 
DO - 1 
Dako 
Cell Signaling 
 
I, II, III 
I, 
II, III 
p63 Ab - 4 Neomarkers I, II, III 
PSA A0562 Dako I 
TOP2B  Atlas Antibodies III 
Ubiquitin FK2 Enzo Life Sciences III 
Wee1A H - 300 
B - 11 
Santa Cruz 
Santa Cruz 
II, III 
III 
1.3. Cell lines (I, II, III) 
Established cancer cell lines, immortalized human fibroblasts and human keratinocytes 
used in these studies were commercially derived or kindly provided by our collaborators 
(Table 5.). The primary prostate and seminal vesicle epithelial cells were isolated from the 
patient samples. The tissue sections were cut into small pieces of less than a 1 mm3, placed 
onto collagen IV –coated petri dishes in an optimized culture medium and kept in culture 
until an epithelial cell population was established. The cells were then collected and stored 
in – 130 °C until further propagated for up to four passages.  
Table 5. Cell lines   
Cell line Description Source Used in 
A375 Human malignant melanoma ATCC II, III 
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HeLa Cervical cancer cell line ATCC III 
HK Human keratinocytes Promocell 
(NHEK) 
III 
HPEC Human prostate epithelial cells Universities 
of Stanford 
and Helsinki 
II, III 
HSVEC Human seminal vesicle epithelial 
cells 
University of 
Helsinki 
III 
LNCaP Metastatic prostate cancer cell line ATCC/Donna 
Peehl 
I, III 
MCF10A Human mammary epithelial cells ATCC II 
Mv1Lu Mink lung epithelial cells ATCC II 
PC3 Prostate cancer cell line ATCC/Donna 
Peehl 
III 
U2OS Osteosarcoma, p53 wt ATCC I, II, III 
WS-1 Human skin fibroblast ATCC II, III 
 
2. Methods 
Method Used in 
5-BrdU labeling I 
Cell culture I, II, III 
Confocal microscopy I, III 
Ex vivo – tissue culture I, II, III 
Fluorescent activated cell sorting (FACS) II, III 
Gene silencing via RNAi III 
Image analysis I, III 
Immunofuorescence I, II, III 
Immunohistochemistry (IHC) I, II, III 
Transfection of cells III 
Transduction of cells III 
TUNEL labeling III 
Western blotting I, II, III 
 
2.1. Ex vivo – tissue culture and DNA damaging treatments (I, II, III) 
Ex vivo – tissue culture method utilizes thin, precision cut tissue slices that can be 
maintained viable for a limited period of time. A cylinder of 8 mm in diameter and several 
centimeters in length was cored fresh from the prostate and seminal vesicle tissue derived 
from surgery. The cylinder was then cut into 300 – 500 µm slices with Krumdieck Tissue 
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Slicer, Alabama Research and Development and transferred onto titanium grids. The slices 
were maintained under rotation and in an optimized culture medium in - 37°C and 5 % CO2 
for 1 - 7 days. R1881 androgen analogue (10 – 20 nmol/l) was added to the culture medium 
if not otherwise indicated. 
The tissue sections were treated with 10 Gy of IR using a calibrated 137Cs γ - source 
(Biomeam 800, STS). Doxorubicin, etoposide, camptothecin, cisplatin, actinomycin D and 
MG132 proteasome inhibitor were all purchases from Sigma - Aldrich, diluted into DMSO 
or ethanol and added to the culture medium at appropriate concentrations. The sections 
were fixed with 10 % formalin, Oy FF Chemicals Ab, after the indicated incubation times 
of 2 – 24 hours. 
2.2. Immunohistochemistry (IHC) (I, II, III) 
The paraffin embedded tissue sections were cut into 4 µm sections and stored in + 4 °C. 
The sections were deparaffinized, rehydrated and the antigens retrieved with heat induced -
epitope antigen retrieval by heating the slices in standard acidic sodium citrate or basic Tris 
- EDTA buffers in a microwave oven (700 – 800 W) for up to 30 minutes. The unspecific 
peroxidase activity was quenched in 0,5 % - 3 % H2O2 –solution, and unspecific 
background signal blocked with 2 - 5 % normal goat serum, Dako and 5 % milk. The 
primary antibodies were diluted into the blocking buffer and incubated for 1h in room 
temperature or overnight in +4°C. The biotinylated secondary antibodies were diluted 1:100 
and incubated for 30 minutes. The ABC Vectastain – Kit was used to enhance the signal 
detected with AEC or DAB+, Dako. The sections were counterstained with hematoxylin, 
mounted and the signal visualized with light microscopy. 
The immunofluorescent staining of tissue sections was carried out similarly to standard 
IHC protocol with the exception of omitting the quenching of unspecific peroxidase 
activity. The secondary antibodies were conjugated with the appropriate fluorescent labels 
and no further signal amplification was required. The counterstaining was carried out with 
Hoechst. 
 
2.3. TUNEL labeling (III) 
Terminal deoxynucleotidyl transferase – mediated dUTP nick end (TUNEL) - labeling was 
used to detect and estimate the number of apoptotic cells in fixed, paraffin embedded ex 
vivo – tissue sections. Terminal deoxynucleotidyl transferase enzyme catalyzes the 
polymerization of labelled nucleotides to the ends of DNA fragments created in apoptotic 
cell death. This allows rapid and sensitive detection of apoptotosis at a single cell level.  
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TUNEL - labeling was carried out with a commercially available In Situ Cell Death 
Detection Kit, TMR red by Roche Diagnostics, where the nucleotides are labelled with a 
red fluorescent marker and apoptotic cells can be directly visualized with fluorescence 
microscopy. The tissue sections were treated according to the manufacturer’s 
recommendations for difficult tissue.  
2.4. 5 - BrdU labeling (I, II, III) 
5 - Bromo - deoxyuridine (5 - BrdU) labeling is used to detect cells in S - phase. 5 - BrdU is 
a thymidine analogue that can be incorporated into newly synthesized DNA and detected 
with antibodies. Cells and tissues were incubated with 50 – 100 µM 5 - BrdU for 30 min – 
2 h, and subsequently fixed and stained for 5 - BrdU. In tissue samples the heat induced 
antigen retrieval is sufficient for exposing the epitope, but with cell culture samples an 
additional treatment with 1,5 M hydrochloric acid for 20 min prior to blocking of 
unspecific signal was required. 
2.5. Cell culture, transfection of cells and gene silencing via RNAi (II, III) 
All the cells were cultured in their appropriate culture media in + 37 °C and 5 % CO2 in a 
humified atmosphere. Cell transfections were carried out with lipofection using commercial 
reagents FuGENE 6 or FuGENE HD transfection reagents, Roche Diagnostics or 
Lipofectamine 2000, Invitrogen, according to the manufacturers recommendations, or by 
electroporation with Gene Pulser II instrument, Bio - Rad. 
RNAi silencing of p53 was carried out with lentiviral transduction. To produce the viral 
particles, 293T cells were transfected with the lentiviral gag, pol, rev and VSV - G 
envelope protein - carrying genes and either pLKO.1 scrambled vector or shRNA targeting 
p53 in pLKO.1 (# TRCN0000010814 or # TRCN000003753, Open Biosystems). The viral 
supernatant was added to the primary cells with 8 mg/ml polybrene to enhance the 
infection, and the media was replaced after 8 hours. IR treatment of the cells was carried 
out on the third day after viral transduction. 
2.6. Fluorescent activated cell sorting (FACS) (II, III) 
FACS analysis allows cell sorting and cell cycle analysis based on cell size and detection of 
their DNA content. Briefly, cultured cells were collected and fixed with 70 % cold ethanol 
overnight. The cells were permeabilized with 0,1 % TritonX - 100 for 5 min, treated with 
0,12 µg/µL RNAse to remove RNA and 0,12 µg/µL propidium iodide to stain the DNA. 
The cell cycle profile of the cells was analyzed with an LSR flow cytometer, BD 
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Biosciences, San Jose, CA and the analyzes performed by ModFit LT vs. 3.1, Verity 
Software House, Topsham, ME. 
2.7. Immunofuorescence (I, II, III) 
The cells were grown on coverslips and fixed with 3,5 % PFA in PBS for 20 min. 
Unspecific binding was blocked with 3 % BSA in PBS for 5 min, the primary antibodies 
diluted into 1 % BSA and incubated in +37 °C for 30 min – 1h. The secondary antibodies 
were diluted 1:200 and incubated in +37 °C for 30 min – 1h. DNA was counterstained with 
DAPI or Hoehcst, and the coverslips mounted with Vectashield, Vector Laboratories. 
2.8. Western blotting (I, II, III)  
Cells were collected, washed and lyzed with urea/Tris buffer (9 M urea/75 mM Tris - HCl, 
pH 7.5 supplemented with 0.15 M 2 - mercaptoethanol), and the pellet was sonicating 
briefly. The protein concentrations were determined by Bio - Rad assay and the proteins 
(50 - 100 mg for UTB lysates) were separated by SDS/PAGE and transferred to 
polyvinylidene fluoride membranes, Immobilon P, Millipore Corporation. Unspecific 
signal was blocked in 3 % BSA or 5 % milk, the primary antibodies diluted in 1 % BSA or 
5 % milk. HRP - conjugated secondary antibodies were diluted in 1 % BSA, and the signal 
detected with enhanced chemiluminescence. 
2.9. Confocal microscopy and image analysis (I, III) 
Confocal images were acquired using Zeiss LSM 510 META confocal microscope, Plan - 
Neofluar 40x/1.3 Oil DIC and Plan - Apochromat 63x/1.4 Oil DIC objectives, LP420, BP 
505 - 530 and LP 560 filters and LSM software release 3.2, Jena, Germany. 
In order to decrease variability in IHC sample analysis, we developed a Matlab based 
image analysis application called Cell Image Segmentation and Classifyer (CISC). CISC is 
able to analyze multiple sets of images from tissue sections labelled with fluorescent 
antibodies. It detects nuclei stained with DAPI or Hoechst based on their fluorescent signal 
intensity, shape and size, and can thereafter be used to quantify nuclear fluorescent signal 
of 1 - 2 proteins detected with appropriate immunofluorescent labels. The detected cells can 
be divided into 2 – 6 different groups based on their mean signal intensity and distribution 
using K - means algorithm. For example, γH2AX signal was classified into four intensity 
groups that were determined as negative, low positive, high positive and apoptotic cells. 
Fluorescence images analyzed with CISC were acquired with Zeiss Axioplan 2 upright 
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epifluorescence microscope, Zeiss Plan - Neofluar objectives, Zeiss AxioCam HRm 14 - bit 
grayscale CCD camera and Zeiss Axiovision 4.6 software. 
2.10. Tissue microarray analysis of Wee1A in prostate tumors (Unpublished) 
Wee1A and p27 levels as well as phosphorylated AKT were determined using IHC from 
two sets of tissue microarrays (TMA) built by Tapio Visakorpi at the University of 
Tampere, and their association with known clinical prognostic markers was estimated. The 
primary prostate cancer TMA consisted of 248 prostate tumors, three cores of each tumor. 
The androgen - resistant prostate tumor TMA consisted of 173 cancer samples. The TMA 
slides were deparaffinized, rehydrated and antigens retrieved by heating the slides in 0.01 
M sodium citrate (pH 6.0) or Tris - EDTA (pH 9.0) buffer (700 – 800 W, up to 20 min). 
The following antibodies and dilutions were used: Wee1A mouse monoclonal Ab (B - 11, 
Santa Cruz Technologies) 1:100, phosphorylated ATK (Cell Signaling) 1:50 and p27 (C - 
19, Santa Cruz) 1:50. p27 and phosphorylated ATK were detected with Vectastain ABC - 
kit, and Wee1A with ADVANCE kit obtained from Dako according to the manufacturers 
instructions.  
The Wee1A staining was inspected blindly by two independent observers and scored 
into the following groups in the primary prostate cancer TMA: negative (165 cases), low – 
moderate nuclear expression (36), high nuclear expression (8), high cytoplasmic 
localization (21) and non - readable (28). In the androgen resistant tumors Wee1A 
expression was classified as negative (71 cases), nuclear expression (5), cytoplasmic 
expression (13), nuclear Wee1 expression combined with homogenous cytoplasmic 
expression (5), nuclear Wee1A expression and strong cytoplasmic localization in a fraction 
of the cells (6) and non - readable (73).  
Statistical analysis was carried out by using Kruskal - Wallis test, chi - square test and 
Mann - Whitney U - test. 
 
 
 
 
59 
Results and discussion 
1. Ex vivo - tissue culture 
Studying the early steps in carcinogenesis by using cancer cell lines has its challenges, and 
mouse reproductive organs have anatomical and physiological differences compared to 
human prostate and seminal vesicles. To overcome these limitations we employed ex vivo – 
tissue culture to study acute DDRs of two benign human tissues, prostate and seminal 
vesicles. We hoped to gain a better understanding of how normal human epithelium deals 
with DNA damage and to lay groundwork for deeper understanding of how genetic 
aberrations start to accumulate in prostate cancer. 
1.1. Setting up the ex vivo – assays (I, III) 
Ex vivo - tissue culture method is based on culturing of thin slices of prostate or seminal 
vesicle tissues for limited periods of time (I, Figure 1A, overview of the method). The 
tissues are collected with informed, written consent of patients undergoing prostatectomy 
due to underlying bladder or prostate cancer. One of the first principles of setting up this 
kind of assays is that patient diagnosis cannot be compromised. To ensure this in our work, 
apex and basis of the cored prostate tissue (8 mm in diameter) and a certain percentage (20 
– 35 %) of collected tissue slices were designated for standard diagnostic evaluation. 
Benign prostate tissue samples were collected from peripheral zone apart from the tumor 
region detected in the needle biopsies, and seminal vesicle material from the superior end of 
the gland.  
Prostate and seminal vesicle tissues were suitable for ex vivo – culturing for multiple 
reasons. As approximately 1000 radical prostatectomies are carried out in Finland every 
year, tissue material is readily available. The solid consistency of prostate and to some 
extent seminal vesicles enabled the precise slicing of the tissue. To support the viability of 
the tissue slices during culturing, the culture medium was optimized to contain the right 
amount of essential amino acids, vitamins, trace elements and growth factors. The survival 
of the prevalent cell types in ex vivo – slices was confirmed with detection of specific 
marker proteins (I, Figures 1, S2, S3 and III, Figure S2), and levels of replication and 
apoptosis were shown to be comparable to standard paraffin embedded tissue sections (I, 
Figures 1D, 2D and S5 and III, Figures S2 and S3).  
There are certain limitations in using ex vivo – assays. First, as patient material was 
obtainable only from radical prostatectomies due to bladder or prostate cancer that mostly 
affect older men, it is possible that aging and age - related pathologies influenced the 
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studied biological responses. It is also possible that some traits that predispose men to 
tumorigenesis were enriched in our material, but excluding these caveats by patient 
selection is not ethically feasible. Second, from a technical standpoint, manipulation of 
tissue responses could only be carried out with radiation, drugs and small molecule 
compounds that have good tissue permeability. Direct modulation of protein expression by 
gene silencing or transfection of the ex vivo – slices is difficult and, to our knowledge, 
reports describing such approaches have not been published. Lentiviral transduction holds 
most promise in achieving this goal, which would make the ex vivo – culture model more 
versatile in studying basic biological mechanisms. 
Due to PSA - screening and earlier detection of prostate cancer, tumor size at the time of 
diagnosis has decreased over time, but with careful patient selection it is also possible to 
collect ex vivo – material of prostate tumor regions. As a proof of principle, Vaira et al. 
(2010) published a similar organotypic assay with 213 tumor samples of 13 different tumor 
types including prostate cancer. In future, organotypic assays could be beneficial in 
optimizing the choice of drug treatment for individual cancer patients as well as validation 
of efficacy of novel therapeutic drugs in human tissue before clinical trials. 
1.2. Development of image analysis tools for quantification of the DNA 
damage response (I) 
IHC is a semiquantitative method. It allows the detection of moderate to major changes in 
protein expression level or localization. It relies on the specificity of the primary antibodies 
used, and sensitivity or detection limit depends on the method of signal amplification and 
visualization. Quantification of IHC results has traditionally been carried out by visual 
estimation of signal intensity and the percentage of positive cells. Visual quantification can 
be influenced by many factors, including personal experience of the surveyor, changes in 
cell density, unspecific background, staining and sample quality.  
CISC has several advantages compared to visual quantification. There is always some 
autofluorescence and other unspecific signal in tissue samples, but the background levels of 
fluorescence can be estimated with appropriate negative controls. After acquisition of the 
images, the data analysis is fairly straightforward and rapid. The number of detected objects 
from one sample (2 - 5 fields/images) varies from several hundred cells to thousands, which 
is sufficient for further statistical analysis. As the same algorithm is used for all images in 
the dataset, there is no variance in parameters that define the assignment into groups. It is 
also possible to use same parameters for other analyses later on, that further minimizes the 
risk of a drift in quantification criteria. In general, CISC allows a more reliable 
quantification of a larger number of cells than what can be achieved with more 
conventional methods.  
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1.3. Early DNA double strand break recognition in prostate and seminal 
vesicle epithelium (I, II, III) 
Considering how resistant prostate adenocarcinomas are to various forms of 
chemotherapeutic drugs (Mike et al., 2006), it was unclear how well DNA damage could 
activate DDR in benign human prostate tissue. One of our hypotheses at the beginning of 
the study was that perhaps DNA damage was unable to activate essential DDR proteins 
already in normal tissue and that this could explain the lack of efficacy of 
chemotherapeutics in tumors. In addition, we were interested in whether there would be 
significant differences in the DDR of major cell types. 
We focused our efforts on studying how early DNA damage recognition would be 
activated by DSBs that are relevant in formation of gene fusions detected in prostate cancer 
(Bartek et al., 2010), and chose to use IR and topoisomerase 2 poisons as damaging agents. 
Based on the induction of ATMSer1981 and its accumulation into DNA damage foci, IR, 
doxorubicin and etoposide all readily activated the early DSB sensor ATM in the three 
major cell types of prostate (I, Figures 6A and S10) and seminal vesicle ex vivo – slices (III, 
Figure 1 and Figure 7.). This is in concordance with ATM being the major regulator of the 
DSB response (Bensimon et al., 2010). It is essential for the repair of 10 – 25 % of DSBs 
(Goodarzi et al., 2008), and defects in its function would render cells sensitive to irradiation 
(Barlow et al., 1996; Rainey et al., 2008; Xu and Baltimore, 1996). Neither prostate nor 
seminal vesicles are particularly radiosensitive. The downstream signal transducer 53BP1 
accumulated into similar foci in all the cell types and at equal magnitude in both prostate 
and seminal vesicles (I Figure 6B, S11, S12, III Figures 1 and S4 and Figure 7.) indicating 
that ATM - pathway activation occurs rapidly and universally after DSBs in these tissues. 
The fact that 53BP1 foci are retained in G0/G1 and terminally differentiated cells supports 
the notion that 53BP1 has cell cycle independent functions, most likely in chromatin 
modification and promotion of NHEJ (Dimitrova et al., 2008; Noon et al., 2010; Xie et al., 
2007). 
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Figure 7. ATM Ser 1981(A) and 53BP1 expression (B) in seminal vesicles after DNA damaging 
treatments. 
1.3.1. The role of H2AX in replication proficient and terminally differentiated cells 
Since their identification in 1998, γH2AX foci have been used as a sensitive marker for 
DSBs (Rogakou et al., 1998). It has been noted that S - phase cells and some cancer cell 
lines have high endogenous levels of γH2AX and further, that other types of DNA damage 
combined with DNA replication may lead to γH2AX induction independent of DSBs. 
However, with careful planning of the experiments, they provide a reliable means to 
estimate the number of DSBs as well as DSB repair kinetics after IR (Lobrich et al., 2010). 
In the prostate and seminal vesicle ex vivo – culture models, the number of replicating cells 
is low (I, Figure 1 and III, Figure S2D) and approximately 99 % of cells are in G0/G1. 
γH2AX detection is thus suitable for analysis of DSBs in both models, and co - 
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immunostaining of γH2AX with cell type specific markers enables comparison between 
different cell types. 
As expected, treatment with IR and TOP2 - inhibitors doxorubicin and etoposide 
resulted in a robust induction of γH2AX foci in both prostate (I, Figures 2A, 2B and S6) 
and seminal vesicle tissue (III, Figure 2 and unpublished data) confirming that these agents 
are potent inducers of DSBs. In prostate tissue, there was a considerable decrease in the 
total levels of γH2AX from 8 hours after IR (more than a 25 - fold induction compared to 
non - treated slices) to 24 hours after IR (less than a 15 - fold induction), most likely due to 
DSB repair. γH2AX levels decreased also from 8 to 24 hours after doxorubicin and 
etoposide treatment, but as the drugs were not washed away from the culture medium, it is 
harder to specify whether this was due to DSB repair or some other adaptation response. In 
order to confirm that the γH2AX levels were not induced by apoptosis (Rogakou et al., 
2000), we carried out a co - immunostaining with cleaved caspase - 3, a known marker for 
apoptosis (I, Figure S5). The apoptotic γH2AX signal was pan - nuclear and highly 
intensive, and it could be separated in the image analysis. The percentage of apoptotic cells 
caused by the DNA damaging treatments of prostate ex vivo – slices ranged from almost 
zero to 10 %, and on average it was 5 %. In seminal vesicle tissue the apoptotic response 
was not quantified, but was confirmed to be low and comparable to prostate by TUNEL - 
assay (III, Figure S3). 
γH2AX is considered essential for efficient DSB repair (Bonner et al., 2008) and has 
been shown to protect genomic integrity in mouse models (Bassing et al., 2002; Bassing et 
al., 2003; Celeste et al., 2003a). It was therefore rather unexpected that after DSBs induced 
by IR or TOP2 - inhibitors, postmitotic luminal cells of prostate tissue did not show as 
strong γH2AX signal as replication proficient basal or stromal cells (I, Figures 5A, 5B and 
S9). Considering that ATM activation occurred in all the cell types, the 10 times lower 
levels of γH2AX signal in luminal cells were not likely caused by disrupted ATM kinase 
function. We hypothesized that maybe the total level of histone variant H2AX itself is low 
in luminal cells, and could verify this with IHC of standard paraffin embedded prostate 
tissues (I, Figure 5C and 5D and Figure 8.). It is tempting to speculate that the lack of 
H2AX would render luminal cells more vulnerable to DSBs and genomic rearrangements, 
but technical limitations of ex vivo – tissue culture (they are not amenable to genetic 
manipulation or transfection, the number of mitotic cells is low and the culture time is 
limited) prevented a more formal proof of the concept. We then turned to the seminal 
vesicle ex vivo – model in search for indirect evidence, but surprisingly, secretory cells of 
seminal vesicle tissue responded in a similar manner. After IR, the levels of γH2AX were 
lower in secretory than in basal epithelial cells (III, Figure 2B). IHC of standard paraffin – 
embedded seminal vesicle tissue confirmed that compared to the basal cells, H2AX - levels 
of secretory seminal vesicles cells are low. Interestingly, some stromal cells of prostate and 
seminal vesicle tissues do not express the expected levels of H2AX (Figure 8.). 
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Furthermore, we noted that the maximal induction of γH2AX after IR treatment seemed to 
occur more rapidly and the resolution of the foci was slower in the seminal vesicle tissue 
(III, Figure 2). It is possible that this reflects differences in DSB repair kinetics between the 
two tissues, but confirmation of this hypothesis would require further studies. 
 
Figure 8. H2AX expression in prostate and seminal vesicle epithelium (A) and stroma (B). 
Arrows indicate H2AX positive cells and arrowheads H2AX negative cells. 
H2AX can be expressed in quiescent cells independently of replication (Wu et al., 
1982). If maintenance of H2AX levels was indispensable in terminally differentiated cells, 
they should be able to produce more H2AX protein in order to compensate the inevitable 
wear and tear. The fact that secretory cells of both prostate and seminal vesicles do not 
retain H2AX at comparable levels to basal cells suggest that either high amounts of H2AX 
are not essential for DSB repair in terminally differentiated cells, or that they tolerate the 
reduction in efficient DSB repair caused by decreased γH2AX. The first possibility is 
supported by our observation that 53BP1 can still accumulate into DNA damage foci and 
be retained there for at least 24 hours after IR. γH2AX has been considered essential for 
recruitment and anchoring of other DSB signaling and repair factors onto damaged 
chromatin (Celeste et al., 2003b; Paull et al., 2000), but maybe this function can be carried 
out with the minimal amount of H2AX present in terminally differentiated cells. It is 
possible that the γH2AX signal amplification covering approximately one megabase around 
a DSB in proliferating cells (Rogakou et al., 1999) is required for other roles of H2AX in 
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protecting genetic integrity, e.g. regulation of G2/M checkpoint (Fernandez - Capetillo et 
al., 2002) or promotion of sister chromatid recombination (Xie et al., 2004). In favour of 
the second possibility, it has been shown that many aspects of DDR are attenuated by 
differentiation. For example, NER, BER and HR are more proficient in cycling than in 
terminally differentiated cells, and the repair of transcribed genes may be the minimal 
requirement of nonproliferating cells. (Fortini and Dogliotti, 2010; Nouspikel, 2007). It is 
hard to imagine that luminal epithelial cells of prostate tissue would tolerate high amounts 
of unrepaired DSBs, especially if they are constantly introduced by AR signaling (Haffner 
et al., 2010). Maybe it is sufficient to either reseal (even incorrectly) broken DNA ends on 
euchromatin regions with ATM - independent NHEJ, or undergo apoptosis. It is difficult to 
speculate how the reduced levels of H2AX would affect its role in apoptosis, other than the 
fact that they clearly do not prevent luminal cells from undergoing this form of 
programmed cell death.  
1.4. p53 responses after DNA damage (I, II, III) 
1.4.1. DSBs and p53 response in ex vivo - cultures 
p53 works as a cellular alarm clock. It constantly monitors intracellular events and responds 
to many forms of stress by regulating transcription of numerous genes. DSBs are known to 
stabilize and activate p53 via several ATM - dependent phosphorylation events that release 
p53 from efficient proteosomal degradation, but there is considerable variation between 
different tissues and cell types. In mouse tissues after IR, ATM is required for p53 – 
mediated apoptosis in thymus, spleen and brain (Gurley and Kemp, 2007). In small 
intestine, lack of AMT results only in a slight delay in p53 induction and apoptosis, and in 
hair follicle epithelial cells ATM is dispensable (Gurley and Kemp, 2007). We were 
interested in how potent p53 inducing DNA damaging agents would act in prostate and 
seminal vesicle tissues, and whether the guardian of the genome would be more vigilant in 
the tumor resistant seminal vesicles. 
We quickly noticed that treatment with IR or doxorubicin resulted in only moderate p53 
stabilization and p21 induction in prostate tissue, although some patients seemed to respond 
more strongly than others (I, Figures 2, 3 and S7). Another TOP2 - inhibitor etoposide, in 
spite of the distinctive induction of γH2AX, was unable to stabilize p53 in prostate. The 
results were similar in seminal vesicle ex vivo - tissues. Treatment with IR led only to 
moderate stabilization of p53 and p21, and more importantly, there were no significant 
differences between prostate and seminal vesicles (III, Figure 3B and 3D). We therefore 
concluded, that DSBs signaling via ATM alone is not sufficient for full p53 activation, and 
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that ATM - γH2AX - 53BP1 signaling and p53 do not differ significantly in differentiated 
cells of the prostate and seminal vesicles. 
Interestingly, p53 stabilization occurred mostly in epithelial but not in stromal cells of 
both prostate and seminal vesicles (I, Figure 4 and III, Figure 3). This is somewhat 
surprising, as under cell culture environment p53 is readily stabilized in normal human 
fibroblasts. Moreover, after IR and also to some extent after other DNA damaging 
treatments, it seemed that basal cells were able to launch the most extensive p53 induction, 
while the highest levels of p21 were detected in secretory cells. It is difficult to explain 
these findings based on our current knowledge on p53, since they are a part of the 
unresolved context dependency - problem (Zilfou and Lowe, 2009). We do not know 
enough about the expression patterns of the many proteins interacting with p53, including 
proteins that contribute to p53 stability (E3 - ligases, DUBs and other enzymes that modify 
p53 post - translationally via phosphorylation, acetylation, methylation or sumoylation), 
DNA binding and transactivation capabilities (such as Mdm4). It is also likely that we have 
only started to understand the many roles of p53 - regulated genes, such as p21, the 
canonical guardian of the G1 cell cycle checkpoint. It is hard to connect the role of p21 
induction in postmitotic secretory cells with the maintenance of G1 arrest. It could rather be 
required to suppress apoptosis of secretory cells after DNA damage.  
1.4.2. Other forms of DNA damage and p53 
The fact that DSB response does not evoke strong p53 activation in differentiated cells of 
prostate and seminal vesicles does not mean that p53 is redundant in these tissues. 
Experiments where degradation of p53 was inhibited either by releasing it from Mdm2 with 
Nutlin - 3 or by blocking proteosomal function with MG132, led to its accumulation (II, 
Figure S11 and I, Figure S8B). They indicated that p53 is constantly being transcribed and 
degraded and can be stabilized in prostate epithelium. Furthermore, TOP1 - inhibitor CPT 
invariably induced high levels of p53 and p21 in prostate and seminal vesicle tissue (I, 
Figures 2, 3, 4, S6 and III, Figure 3), as well as by treatments with actinomycin D (I, Figure 
S8A) and Dichloro - ribofuranosylbenzimidazole (DRB). Common to all these drugs is that 
they are potent inhibitors of transcription. We therefore suggest that transcriptional stress in 
differentiated cells leads to p53 stabilization. 
There has been some disagreement over whether IR or DSBs affect transcription. It is 
possible that ribosomal RNA transcription is transiently reduced by DSBs in an ATM - 
dependent manner (Kruhlak et al., 2007). Recent evidence suggests that ATM mediates 
histone H2A ubiquitylation via RNF8 and RNF168 (Doil et al., 2009; Mailand et al., 2007; 
Stewart et al., 2009) to inhibit transcription in chromosomal regions close to DBS, but does 
not cause a global reduction in transcription (Shanbhag et al., 2010). Thus, it is possible 
that the stronger or more universal the disturbance in transcription is, the better is 
 
 
 
 
67 
stabilization of p53. Perhaps doxorubicin, being a DNA intercalating agent, is able to 
inhibit transcription more potently than etoposide that is thought to affect TOP2 via protein 
- protein interactions. 
There is some evidence on how p53 could detect transcriptional stress. One possibility is 
that nucleolus, the transcription site of ribosomal RNA, acts as a stress sensor for p53, and 
impaired nucleolar function is the common signal for stabilization of p53 (Rubbi and 
Milner, 2003). Other option is that p53 can sense stalling of RNA polymerase II more 
directly via its interactions with components of the transcriptional machinery (Laptenko 
and Prives, 2006; Riley et al., 2008). Stabilized p53 could then restore intracellular balance 
by activating or repressing transcription of appropriate target genes according to a cell type 
and the nature of DNA damage (Zhao et al., 2000). 
1.5. The prerequisites of TMPRSS2 - ERG - fusions in prostate and seminal 
vesicles (III and unpublished data) 
According to recent publications, TMPRSS2 - ERG - fusions arise not as random events 
but as a result from misrepair of certain transcription - associated DSBs (Bartek et al., 
2010). All the specific requirements for the formation of gene fusions in prostate cancer 
have probably not yet been characterized, but several proteins have been implicated. The 
initial DSBs are formed by the concerted action of AR and TOP2B (Haffner et al., 2010). 
These recombinogenic breaks activate ATM - pathway, and are repaired by NHEJ - and 
poly (ADP - ribose) polymerase 1 (PARP1) –dependent manner (Haffner et al., 2010; Lin 
et al., 2009). We were therefore interested in finding out whether there would be 
endogenous differences in the levels of certain key recombinogenic proteins between 
seminal vesicles and prostate tissue. 
Seminal vesicles and prostate are androgen dependent in their tissue maintenance and 
secretory function, and secretory cells of both express AR (Figure 9A and Laczko et al., 
2005). Under normal growth control both tissues express TOP2B mainly in their basal cell 
layer (Figure 9B), and we have not detected major differences in the early DSB - detection 
measured by ATM or 53BP1 activation or γH2AX levels (III, Figures 1 and 2 and S4). 
Further, TOP2 - inhibitors doxorubicin and etoposide are able to induce DDR at a similar 
scale after DSB in both tissues (I, Figures 2 - 4 and S6, S9 - S11 and unpublished data). 
Why then androgen signaling that results in TMPRSS2 - ERG - fusions in prostate would 
not do so in seminal vesicles?  
Benign seminal vesicle epithelium has many characteristics of neoplastic changes, 
including irregularity, prominent nucleoli and presence of atypical cells (Arber and 
Speights, 1991). To ascertain that seminal vesicle tissue does not feature the fusion, we 
carried out an IHC analysis of 24 prostate and seminal vesicles samples using an antibody 
that has been reported to detect ERG overexpression reliably from paraffin - embedded 
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samples (Park et al., 2010). While 8 out of the 19 prostate tumors in the set were ERG - 
fusion positive, we could not detect any ERG - positive epithelial regions in seminal vesicle 
samples, suggesting that under similar circumstances TMPRSS2 - ERG fusions occur 
mainly in prostate tissue (Figure 9C and D). More thorough investigation on the NHEJ - 
pathway and other DDR proteins is required to further pinpoint what renders prostate tissue 
so susceptible to chromosomal rearrangements. It is also possible that androgen signaling in 
seminal vesicles produces less or no DSBs, or that the amount of contributing endogenous 
or exogenous DNA damage differs markedly between the two tissues. In human tumors, 
TMPRSS2 - ERG - fusions arise in PIN - lesions and promote transition into cancer (Carver 
et al., 2009). It is also possible that seminal vesicle epithelium has better proliferative 
control that prevents PIN - formation, and thus seminal vesicles never end up in the 
situation where TMPRSS2 - ERG - fusions arise in prostate tissue. 
 
Figure 9. AR is expressed in the secretory (A) and TOP2B in the basal cells (B) in normal human 
prostate and seminal vesicle tissues. ERG - overexpression (C, D) can be detected in 
prostate tumors but not in the normal epithelium of prostate and seminal vesicles. * 
indicates ERG-positive endothelial cells.  
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2. DNA damage response in human primary cells of prostate and 
seminal vesicles 
2.1. Primary cell isolation and characterization (II, III) 
HPECs and human seminal vesicle epithelial cells (HSVECs) are primary cells isolated 
from histologically normal regions of prostate or seminal vesicles. Tissue material for our 
studies was collected similarly to ex vivo – tissue cultures, from patients undergoing radical 
prostatectomy due to bladder or prostate cancer. Briefly, a part of the cored tissue cylinder 
was dedicated for HPEC or HSVEC culture, cut into small pieces (~ 1 - 3 mm3) and placed 
onto collagen IV – coated cell culture dishes. Optimized culture medium that contains 
epithelial cell – specific growth factors and other supplements, supports the growth of a 
population of epithelial but not of stromal cells. We and others have successfully used this 
method to isolate primary prostate epithelial cells, and they are also commercially available 
(Garraway et al., 2003; Peehl, 2005; Uzgare et al., 2004). As described in the chapter on 
prostate tissue structure and function, primary prostate epithelial cells are considered to be 
transit amplifying cells. 
To our knowledge, primary epithelial cells of seminal vesicles have not been 
investigated elsewhere. HSVECs represent a similar cell population as HPECs (III, Figure 
S1). They have a characteristic appearance of epithelial cells: round morphology and 
tendency to adhere to each other and form cobblestone like surfaces (Figure 10.).  
 
Figure 10. (A) Early HSVECs are small, round and grow apart from each other. (B) The 
archetypical cobblestone appearance of more differentiated HSVECs. 
 
Consistent with a basal cell origin, they express basal cell markers such as epithelial 
cytokeratin 5 and p63 and have low levels of p27 and AR. HSVECs have a finite lifespan in 
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culture. They gradually lose their potential to proliferate and eventually undergo 
senescence. Therefore, both HSVECs and HPECs most likely represent transit amplifying 
cells. 
2.2. Cell cycle checkpoints in HPECs and HSVECs (II, III) 
HSVECs and HPECs differ dramatically in their ability to activate cell cycle checkpoints 
after DSBs. HPECs do not have a G1 - checkpoint arrest, they show RDS and lack also a 
robust G2/M arrest after IR (Girinsky et al., 1995 and II, Figure 1), which is quite 
surprising considering that they are benign cells. This deviation in cell cycle checkpoints is 
not likely due to a failure in DSB detection, as early damage sensors Nbs1, Rad50 and 
γH2AX accumulate into DNA damage induced foci in HPECs. Equally, the effector kinase 
CHK2 is phosphorylated on its threonine 68, and CDC25A is degraded indicating that 
ATM - CHK2 - CDC25A - pathway is functional. However, the HPECs do not display 
inhibitory Tyr 15 phosphorylations on CDK2 and CDK1 after IR, which is consistent with 
their inability to arrest in cell cycle after DNA damage (II, Figure 3). HSVECs on the 
contrary, are able to activate both G1 and G2 –arrest. This is shown by a significant 
increase in the number of cells in G2 24 hours after IR, and a concomitant decrease in the 
number of replicating HSVECs from 17 % to less than 5 % (III, Figure 4).  
Severe problems in DSB repair usually lead to increased radiosensitivity. This is 
especially prominent in cells with defective activation of DNA damage signaling or repair 
such as in ATM null cells. HPECs are not particularly radiosensitive, indicated by the lack 
of a significant increase in apoptotic sub - G1 - population in flow cytometry analysis after 
IR, so they are presumably able to repair DSBs despite their lack of cell cycle checkpoint 
enforcement. The checkpoints are thought to give cells more time to repair DNA damage. It 
is therefore possible that the lack of time forces HPECs to repair DSBs quickly at the cost 
of accuracy, and maybe this predisposes them to genomic translocations. As HSVECs are 
more proficient in their DNA - damage induced cell cycle checkpoints, it would be 
interesting to compare the success rate of DSB repair between HPECs and HSVECs.  
2.3. p53 and the G1 arrest (II, III) 
Prostate and seminal vesicle ex vivo – tissue slices did not differ notably in respect of p53 
activation after DSBs. It was therefore surprising that there was such a difference between 
HSVECs and HPECs (III, Figure 5). HSVECs were able to stabilize p53 rapidly within two 
hours after IR, and a moderate and transient p21 induction was detectable. This pattern 
differs from many other primary epithelial cells, including HPECs (Girinsky et al., 1995), 
HMECs (Huper and Marks, 2007; Meyer et al., 1999), human keratinocytes (Flatt et al., 
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1998), human bronchial epithelial cells (Gadbois and Lehnert, 1997) or mouse hepatocytes 
(Bellamy et al., 1997). These data indicate that the regulatory network of p53 is wired 
differentially in HSVECs compared to many other epithelial cells. They also suggest that 
p53 in HSVECs may also respond more strongly to other stresses, which could offer one 
explanation for the question why seminal vesicle carcinomas are so exceedingly rare. On 
the other hand, the levels of p53 and p21 induction were not as robust as in normal human 
fibroblasts, although p21 expression levels responded to p53 silencing. It seems that 
epithelial cells cannot afford a permanent cell cycle withdrawal that has been shown to 
occur in human fibroblasts (Di Leonardo et al., 1994). 
We could also detect p53 in DNA damage induced foci that colocalized with γH2AX in 
both HSVECs and HPECs. Similar p53 foci have been observed in confluent G0/G1 
primary fibroblasts, where they mainly consisted of serine 15 phosphorylated subpool of 
p53 (Al Rashid et al., 2005). The role of this chromatin bound p53 has not been 
exhaustively clarified, but it is yet another indication of the context dependence problem of 
p53. Why is serine 15 phosphorylation of p53 retained in HPECs after IR, while the overall 
p53 stabilization is lacking? Is it only a rudiment of active ATM that is still able to 
phosphorylate its target protein, or does it have some irreplaceable role in primary cells? It 
is clearly not able to maintain functional G1 arrest in HPECs, but may be required for 
potentiating transactivation capabilities or apoptosis launched by p53. This view is 
supported by the mouse models where serine 15 phosphorylation has been constitutively 
prevented (Armata et al., 2007; Chao et al., 2003). Thymocytes of these mice are partially 
defective in apoptosis, and transactivation of several p53 target genes is reduced in 
fibroblasts without abrogation of the cell cycle arrest. 
2.4. Wee1A and the G2 arrest (II, III) 
Other striking feature in HSVECs that could explain their cell cycle checkpoint proficiency 
was their high expression levels of Wee1A, the kinase responsible for inhibitory tyrosine 15 
phosphorylations on CDK1 (III, Figure 6). Wee1A expression in HSVECs was 
approximately 8 times higher than in HPECs and comparable to many cancer cell lines. The 
cause for this difference is unknown. It is possible than Wee1A protein is degraded more 
efficiently in HPECs. Of the 11 cell lines tested, HPECs had the lowest levels of Wee1A, 
and MG132 proteasome inhibitor was able to increase Wee1A levels somewhat in HPECs. 
Furthermore, the phosphodegron Wee1 mutant that cannot be phosphorylated by Plk1 and 
Cdk1 and thus escapes degradation via β - TrCP (Watanabe et al., 2004; Watanabe et al., 
2005), was able to increase tyrosine 15 phosphorylation of CDK2 significantly (II, Figure 
4). It is also possible that Wee1A expression levels in HPECs do not increase in S and 
G2/M phases as robustly as in HSVECs. 
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2.4.1. Wee1A in prostate tumors (Unpublished data)  
HPECs lack DSB induced G2 arrest because of low levels of Wee1A. In normal prostate 
tissue, nuclear Wee1A is expressed in basal epithelial cells that unlike luminal cells have 
replicative potential (II, Figure 4B). Next, we asked whether Wee1A could also be a 
prognostic marker in prostate cancer. Preliminary studies of prostate tumors indicated that 
levels and localization of Wee1A were deregulated. Noting that in prostate cancer 
PTEN/AKT pathway is compromised with high frequency and that AKT has been shown to 
inactivate Wee1A by translocating it into cytoplasm (Katayama et al., 2005), we carried out 
an extensive prostate tumor tissue microarray - analysis (in collaboration with Dr. Tapio 
Visakorpi, University of Tampere) and compared expression levels and localization of 
Wee1A, phosphorylated i.e. active AKT, and p27, which is another AKT - target altered in 
prostate cancer. Both primary tumors (N=258) and tumors resistant to androgen ablation 
therapy (N=173) were included in the study. 
We were able to establish the expression patterns of Wee1 in 230 primary prostate 
cancer cases and in 100 androgen resistant tumors (Figure 11.). Most prostate tumors in 
both groups (71%) were negative for Wee1. Nuclear Wee1 expression was detected in 19,1 
% of primary tumors and in 16 % of androgen resistant tumors, and cytoplasmic Wee1 in 
9,1% and 13% of cases (unpublished observations). None of the Wee1 expression groups 
associated with disease progression or time to progression, so we were not able to 
demonstrate that Wee1 has a prognostic role in prostate cancer. Interestingly, nuclear 
Wee1A associated with higher Ki67 expression (p=0.0337) and bigger tumor size (pT2 vs. 
pT3, p=0.0157) in the group of primary tumors, which is in accordance with its elevated 
expression levels in S - and G2 - phases of the cell cycle. The association between nuclear 
Wee1A and Ki67 expression was detected also in the group of hormone refractory tumors 
(p=0.0354). Phosphorylated AKT and surprisingly, nuclear p27 correlated with high Ki67 
percentage (p<0,0001 and p=0,0374), as did phosphorylated AKT and cytoplasmic Wee1A 
(p=0.0365). Phosphorylated AKT has been published to be a strong predictor of 
biochemical recurrence (Ayala et al., 2004), but in our analysis it did not associate with 
poor prognosis. In conclusion, in prostate tumors nuclear Wee1A levels are upregulated in 
response to high proliferation rates. It therefore seems that the constraints that prevent high 
expression of Wee1A in HPECs are removed during tumorigenesis. 
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Figure 11. Wee1A expression patterns in prostate tumors. 
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Conclusions 
Faulty repair of DSBs contributes to prostate tumorigenesis. Studying DSB detection and 
repair mechanisms in normal prostate tissue is therefore important for understanding the 
molecular mechanisms leading to prostate cancer. Seminal vesicles provide a good model 
for comparison, as they are remarkably resistant against neoplastic changes. Moreover, 
better understanding of the factors that prevent accumulation of genetic aberrations in 
seminal vesicle epithelium may reveal potential targets for cancer therapy and even cancer 
prevention. 
In this work we studied early DDR using novel models of benign human prostate and 
seminal vesicles. Ex vivo – tissue culture offers possibilities that are not attainable by 
routine cell culture. They maintain the differentiated cell types, heterotopic interactions and 
supporting stroma, and are a good means to study the effects of therapeutic drugs on human 
tissue. 
It is evident that many factors, including cell type and differentiation, influence DDR in 
ways that are sometimes surprising. We found out that terminally differentiated secretory 
cells express only low levels of histone H2AX, which is considered an essential component 
of successful DSB signaling. This suggests that either DSB signaling is less stringent in 
cells that no longer need to proliferate, or that H2AX has distinct, dose – dependent roles in 
different cell types. Function of many DDR proteins is limited into specific phases of the 
cell cycle, and the expression patterns of many of the newest members of the DSB 
signaling pathways have not been thoroughly investigated. We need a more detailed 
understanding of the availability of DDR factors and their biologic activity in various 
tissues in order to combine the different DDR pathways into a meaningful system.  
Primary seminal vesicle epithelial cells proved to have more effective DSB induced cell 
cycle checkpoints, and p53 activation than primary prostate epithelial cells. Furthermore, 
the levels of Wee1A were higher in seminal vesicle epithelial cells. These findings were 
surprising, as we were not able to detect significant differences in the main DSB signaling 
pathways between the two tissues using ex vivo – models. These results suggest that cell 
proliferation in certain tissues may be a double - edged sword. It is necessary for tissue 
renewal after cellular damage, but at the same time may render differentiated cells more 
liable to acquiring genetic aberrations. 
p53 activation and inhibition of Wee1A by small molecule compounds such as Nutlin - 3 
and MK - 1775 are both being investigated as potential strategies for cancer therapy. Our 
results indicate that robust p53 activation in prostate epithelium can be achieved by 
administration of Nutlin - 3 and drugs causing transcriptional stress, suggesting that p53 
activation is achievable in prostate tumors. On the other hand, p53 pathway activation may 
not be as efficient in prostate cancer as in some other cancer types due to inherent 
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differences in the p53 signaling pathway that already exist between benign prostate 
epithelium and other tissues. Similarly, the potential benefit of Wee1A inhibition in 
prostate cancer is uncertain, as prostate epithelial cells express only low levels of Wee1A 
and most prostate tumors are negative for Wee1A. The applicability of both these 
approaches require further studies, in which models such as primary cell and ex vivo – 
tissue culture presented here may prove to be useful.  
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